UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 8-K/A

CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 31, 2017

Surgery Partners, Inc.

(Exact Name of Registrant as Specified in Charter)

Delaware001-3757647-3620923(State or Other Jurisdiction
of Incorporation)(Commission
File Number)(IRS Employer
Identification No.)

40 Burton Hills Boulevard, Suite 500 Nashville, Tennessee 37215

(Address of Principal Executive Offices) (Zip Code)

(615) 234-5900

(Registrant's Telephone Number, Including Area Code)

Not Applicable

(Former Name or Former Address, If Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company o

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

Item 2.01 Completion of Acquisition or Disposition of Assets

As previously reported by Surgery Partners, Inc., a Delaware corporation (the "Company") in its Current Report on Form 8-K filed on September 1, 2017 (the "Original Filing"), on August 31, 2017, the Company, completed its acquisition of NSH Holdco, Inc., a Delaware corporation ("NSH"). Pursuant to the terms of the Agreement and Plan of Merger, dated as of May 9, 2017, by and among the Company, SP Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Company ("Merger Sub"), NSH, and IPC / NSH, L.P. (solely in its capacity as sellers' representative), as amended by that certain Letter Amendment, dated as of July 7, 2017 (as amended, the "Merger Agreement"), Merger Sub merged with and into NSH with NSH continuing as the surviving corporation and a wholly owned subsidiary of the Company (the "Merger"). The Company hereby files this Amendment No. 1 to the Original Filing to provide the financial statements and pro forma financial information required by Item 9.01(a) and Item 9.01(b) of Form 8-K in connection with the Merger.

The foregoing description of the Merger Agreement and the Merger does not purport to be complete and is subject to, and qualified in its entirety by the full text of the Merger Agreement, a copy of which is filed as Exhibit 2.1 to the Company's Current Report on Form 8-K filed May 11, 2017, and the full text of the amendment to the Merger Agreement, a copy of which is filed as Exhibit 2.1 to the Company's Current Report on Form 8-K filed July 11, 2017, both of which are incorporated into this Item 2.01 by reference herein.

Item 9.01. Financial Statements and Exhibits.

(a) Financial Statements of Businesses Acquired.

The following financial statements of NSH are filed as Exhibit 99.1 to this Current Report on Form 8-K and are incorporated herein by reference:

- Consolidated Balance Sheets as of December 31, 2016 and 2015
- · Consolidated Statements of Operations for the years ended December 31, 2016, 2015 and 2014
- Consolidated Statements of Changes in Equity for the years ended December 31, 2016, 2015 and 2014
- · Consolidated Statements of Cash Flows for the years ended December 31, 2016, 2015 and 2014
- Notes to Consolidated Financial Statements

The following interim financial statements of NSH are filed as Exhibit 99.2 to this Current Report on Form 8-K and are incorporated herein by reference:

- Condensed Consolidated Balance Sheets as of June 30, 2017 (unaudited) and December 31, 2016
- Unaudited Condensed Consolidated Statements of Operations for the three months ended June 30, 2017 and June 30, 2016
- Unaudited Condensed Consolidated Statements of Operations for the six months ended June 30, 2017 and June 30, 2016
- Unaudited Condensed Consolidated Statement of Changes in Equity for the six months ended June 30, 2017
- Unaudited Condensed Consolidated Statements of Cash Flows for the six months ended June 30, 2017 and June 30, 2016
- Notes to Condensed Consolidated Financial Statements (unaudited)

(b) Pro Forma Financial Information.

The following unaudited pro forma combined condensed consolidated financial information is filed as Exhibit 99.3 to this Current Report on Form 8-K and is incorporated herein by reference:

- Unaudited pro forma condensed combined [consolidated] balance sheet as of June 30, 2017
- Unaudited pro forma condensed combined [consolidated] statement of operations for the year ended December 31, 2016 and the six months ended June 30, 2017
- Notes to unaudited pro forma condensed combined [consolidated] financial information

The pro forma financial information is presented for informational purposes only and does not purport to represent what the Company's results of operations or financial position would have been had the transactions reflected occurred on the dates indicated or to project the Company's financial position as of any future date or the Company's results of operations for any future period.

(d) Exhibits.

Exhibit

Number	Description
2.1	Agreement and Plan of Merger by and among Surgery Partners, Inc., SP Merger Sub, Inc., NSH Holdco, Inc. and IPC / NSH, L.P., dated as of May 9, 2017 (incorporated herein by reference to Exhibit 2.1 to the Company's Current Report on Form 8-K filed May 11, 2017).*
2.2	Letter Amendment to Merger Agreement, by and among Surgery Partners, Inc., SP Merger Sub, Inc., NSH Holdco, Inc. and IPC / NSH, L.P., dated as of July 7, 2017 (incorporated herein by reference to Exhibit 2.1 to the Company's Current Report on Form 8-K filed July 11, 2017)*
23.1	Consent of Independent Auditors
99.1	Historical consolidated financial statements of NSH Holdco, Inc.
99.2	Historical consolidated interim financial statements of NSH Holdco, Inc.
99.3	Unaudited pro forma combined condensed consolidated financial information of Surgery Partners, Inc.

^{*} Schedules and/or Exhibits have been omitted pursuant to Item 601(b)(2) of Regulation S-K. The Company agrees to furnish a supplemental copy of any omitted schedule or exhibit to the Securities and Exchange Commission upon request.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

SURGERY PARTNERS, INC.

By: <u>/s/ Teresa F. Sparks</u> Teresa F. Sparks

Executive Vice President and Chief Financial Officer

Date: November 8, 2017

EXHIBIT INDEX

Exhibit

Number	Description
2.1	Agreement and Plan of Merger by and among Surgery Partners, Inc., SP Merger Sub, Inc., NSH Holdco, Inc. and IPC / NSH, L.P., dated as of May 9, 2017 (incorporated herein by reference to Exhibit 2.1 to the Company's Current Report on Form 8-K filed May 11, 2017).*
2.2	Letter Amendment to Merger Agreement, by and among Surgery Partners, Inc., SP Merger Sub, Inc., NSH Holdco, Inc. and IPC / NSH, L.P., dated as of July 7, 2017 (incorporated herein by reference to Exhibit 2.1 to the Company's Current Report on Form 8-K filed July 11, 2017)*
23.1	Consent of Independent Auditors
99.1	Historical consolidated financial statements of NSH Holdco, Inc.
99.2	Historical consolidated interim financial statements of NSH Holdco, Inc.
99.3	<u>Unaudited pro forma combined condensed consolidated financial information of Surgery Partners, Inc.</u>

^{*} Schedules and/or Exhibits have been omitted pursuant to Item 601(b)(2) of Regulation S-K. The Company agrees to furnish a supplemental copy of any omitted schedule or exhibit to the Securities and Exchange Commission upon request.

CONSENT OF INDEPENDENT AUDITOR'S

We consent to the incorporation by reference in the Registration Statement on Form S-8 of Surgery Partners, Inc. of our report dated November 8, 2017 on the consolidated financial statements of NSH Holdco, Inc. , which is included in this Current Report on Form 8-K.

/s/ Crowe Horwath LLP

Chicago, Illinois November 8, 2017

Annual Consolidated Financial Statements

INDEX

<u>DESCRIPTION</u>	<u>PAGE</u>
Independent Auditor's Report	2
Consolidated Balance Sheets as of December 31, 2016 and 2015	3
Consolidated Statements of Operations for the years ended December 31, 2016, 2015 and 2014	4
Consolidated Statements of Changes in Equity for the years ended December 31, 2016, 2015 and 2014	5
Consolidated Statements of Cash Flows for the years ended December 31, 2016, 2015 and 2014	6
Notes to Consolidated Financial Statements.	7

INDEPENDENT AUDITOR'S REPORT

The Audit Committee of the Board of Directors NSH Holdco, Inc. Chicago, Illinois

Report on the Financial Statements

We have audited the accompanying consolidated financial statements of NSH Holdco, Inc., which comprise the consolidated balance sheets as of December 31, 2016 and 2015, and the related consolidated statements of operations, changes in equity, and cash flows for each of the three years in the period ended December 31, 2016, and the related notes to the consolidated financial statements.

Management's Responsibility for the Financial Statements

Management is responsible for the preparation and fair presentation of these consolidated financial statements in accordance with accounting principles generally accepted in the United States of America; this includes the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of consolidated financial statements that are free from material misstatement, whether due to fraud or error.

Auditor's Responsibility

Our responsibility is to express an opinion on these consolidated financial statements based on our audits. We conducted our audits in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the consolidated financial statements. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the consolidated financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity's preparation and fair presentation of the consolidated financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity's internal control. Accordingly, we express no such opinion. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Opinion

In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of NSH Holdco, Inc., as of December 31, 2016 and 2015, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2016 in accordance with accounting principles generally accepted in the United States of America.

/s/ Crowe Horwath LLP

Chicago, Illinois

November 8, 2017

Consolidated Balance Sheets

(In thousands, except share information)

(In thousands, except snare information)		December 31, 2016		December 31, 2015
Assets				
Current assets:				
Cash	\$	29,677	\$	38,673
Patient accounts receivable (less allowances for doubtful accounts of \$21,386 and \$21,795 in 2016 and 2015, respectively)		100,279		94,246
Supplies		14,910		14,430
Receivables from affiliates		635		812
Income tax receivable		4,392		_
Prepaid expenses and other current assets		10,347		12,575
Current assets - discontinued operations		779		3,196
Total current assets		161,019		163,932
Long-term assets:				
Property and equipment, net		192,467		185,312
Goodwill		665,534		654,552
Intangible assets, net		101,625		104,212
Investments in unconsolidated affiliates		9,163		9,604
Other long-term assets		4,842		4,661
Long-term assets - discontinued operations		1,378		1,378
Total assets	\$	1,136,028	\$	1,123,651
Liabilities and Equity				
Current liabilities:				25.000
Accounts payable	\$	37,151	\$	35,982
Accrued expenses		32,019		32,603
Income taxes payable		2.650		2,048
Current maturities of term loan and long-term note		3,650		3,650
Current maturities of capital leases and other long-term debt		19,867		12,453
Current liabilities - discontinued operations Total current liabilities	<u></u>	93,032		236 86,972
Long-term liabilities:		93,032		00,372
Term loan and long-term note, net, less current maturities		446,961		447,967
Capital leases and other long-term debt, net, less current maturities		58,865		45,006
Deferred financing obligations		39,731		40,504
Deferred tax liability		46,789		35,544
Other long-term liabilities		2,085		2,038
Long-term liabilities - discontinued operations		338		687
Total liabilities	<u> </u>	687,801	<u></u>	658,718
Commitments and contingencies	·	007,001		050,710
Noncontrolling interests - redeemable		122,081		127,171
Equity		122,001		127,171
Controlling shareholders' equity:				
Preferred stock, \$0.01 par value, 325,000 shares authorized, 117,287 shares issued and outstanding at December 31, 2016 and 2015		1		1
$Common\ stock, \$0.01\ par\ value, 325,000\ shares\ authorized, 138,482\ and\ 137,476\ shares\ issued\ and\ outstanding\ at\ December\ 31,\ 2016\ and\ 2015,\ respectively$		1		1
Additional paid-in capital		77,324		97,111
Retained earnings		82,637		74,078
Total controlling shareholders' equity		159,963		171,191
Noncontrolling interests - non-redeemable		166,183		166,571
Total equity		326,146		337,762
Total liabilities and equity	\$	1,136,028	\$	1,123,651

See accompanying notes to consolidated financial statements.

Consolidated Statements of Operations

(In thousands)

	Years ended December 31,			
	2016	2015	2014	
Revenues				
Patient service revenues (net of contractual allowances and discounts)	\$ 589,946	\$ 514,058	\$ 322,292	
Less: Provision for bad debts	(13,561)	(15,047)	(7,651)	
Net patient service revenue	576,385	499,011	314,641	
Management fees and other revenue	6,307	7,193	4,257	
Total revenues	582,692	506,204	318,898	
Operating Expenses				
Salaries, supplies and other operating expenses	449,040	381,451	251,925	
Corporate, general and administrative expenses	20,145	23,260	20,572	
Depreciation and amortization	30,828	31,765	16,084	
Total operating expenses	500,013	436,476	288,581	
Operating income	82,679	69,728	30,317	
Other Income (Expense)				
Interest expense, net	(35,575)	(27,448)	(14,882)	
Other income	3,156	3,870	6,564	
Gain on acquisitions	_	62,813	4,610	
Gain on deconsolidation	_	1,327	_	
Loss on early extinguishment of debt	_	(5,335)	_	
Gain (loss) on lease abandonment	_	509	(5,874)	
Loss on sale of assets, net	(587)	(59)	(752)	
Equity in earnings of unconsolidated affiliates	2,796	6,031	12,785	
Total other income (expense), net	(30,210)	41,708	2,451	
Income before taxes, discontinued operations and noncontrolling interests	52,469	111,436	32,768	
Income tax expense	(6,837)	(29,515)	(5,636)	
Net income from continuing operations	45,632	81,921	27,132	
Discontinued operations:				
Income from discontinued operations	235	350	185	
Gain on disposal, net	_	17	2,334	
Gain on contract termination	_	_	2,000	
Income tax benefit (expense)	(526)	920	(2,981)	
Income (loss) from discontinued operations, net	(291)	1,287	1,538	
Net income	45,341	83,208	28,670	
Less: Net income attributable to noncontrolling interests	(36,782)	(33,139)	(21,403)	
Net income attributable to NSH Holdco, Inc.	\$ 8,559	\$ 50,069	\$ 7,267	

See accompanying notes to consolidated financial statements.

Consolidated Statement of Changes in Equity

(In thousands, except shares)

	Preferred Stock Common Stock Additional P		dditional Paid	Retained	Noncontrolling Interests - non-		Total			
	Shares	Amount	Shares	Amount	11	In Capital	Earnings	redeemable		Equity
Balance: January 1, 2014	118,052	\$ 1	132,302 \$	1	\$	132,916 \$	16,742	\$ 1,491	\$	151,151
Noncash stock compensation	_	_	_	_	\$	206	_	_	\$	206
Shares issued	_	_	2,037	_		204	_	_		204
Repurchase of shares	(765)	_	(850)	_		(850)	_	_		(850)
Dividends paid	_	_	_	_		(35,700)	_	_		(35,700)
Net income	_	_	_	_		_	7,267	21,403		28,670
Distributions to noncontrolling interests	_	_	_	_		_	_	(23,452)		(23,452)
Change in noncontrolling interests from other activity, net	_	_	_	_		_	_	17,072		17,072
Change in noncontrolling interests - redeemable	_	_	_	_		_	_	(12,145)		(12,145)
Balance: December 31, 2014	117,287	\$ 1	133,489 \$	1	\$	96,776 \$	24,009	\$ 4,369	\$	125,156
Noncash stock compensation	_	_	_	_	\$	293	_	_	\$	293
Shares issued	_	_	5,668	_	Ψ	567	_	_	Ψ	567
Repurchase of shares	_	_	(1,681)	_		(525)	_	_		(525)
Net income	_	_	_	_		_	50,069	33,139		83,208
Distributions to noncontrolling interests	_	_	_	_		_	_	(31,073)		(31,073)
Change in noncontrolling interests from acquisitions, deconsolidation and disposal, net	_	_	_	_		_	_	188,453		188,453
Change in noncontrolling interests from other activity, net	_	_	_	_		_	_	212		212
Change in noncontrolling interests - redeemable	_	_	_	_		_	_	(28,529)		(28,529)
Balance: December 31, 2015	117,287	\$ 1	137,476 \$	1	\$	97,111 \$	74,078	\$ 166,571	\$	337,762
Noncash stock compensation	_	_	_	_	\$	203	_	_	\$	203
Shares issued		_	1,155	_		124	_	_		124
Repurchase of shares	_	_	(149)	_		(105)	_	_		(105)
Dividends paid	_	_	_	_		(20,009)	_	_		(20,009)
Net income	_	_	_	_			8,559	36,782		45,341
Distributions to noncontrolling interests	_	_	_	_		_	_	(41,060)		(41,060)
Change in noncontrolling interests from other activity, net	_	_	_	_		_	_	(1,200)		(1,200)
Change in noncontrolling interests - redeemable	_	_	_	_		_	_	5,090		5,090
Balance: December 31, 2016	117,287	\$ 1	138,482 \$	1	\$	77,324 \$	82,637	\$ 166,183	\$	326,146

 $See\ accompanying\ notes\ to\ consolidated\ financial\ statements.$

Consolidated Statements of Cash Flows

(In thousands) Years ended December 31,

(In thousands)	 Years ended December 31,				
	 2016		2015		2014
Cash flows from operating activities					
Net income	\$ 45,341	\$	83,208	\$	28,670
Adjustments to reconcile net income to net cash provided by operating activities:					
Provision for bad debts	13,561		15,047		7,651
Depreciation and amortization	30,828		31,765		16,084
Amortization of debt discount and deferred debt issuance costs	2,645		2,151		1,241
Equity in earnings of unconsolidated affiliates	(2,796)		(6,031)		(12,785)
Deferred income taxes	11,103		18,627		6,554
Stock option and other noncash compensation expense	203		293		206
Gain on acquisitions	_		(62,813)		(4,610)
Gain on deconsolidation	_		(1,327)		_
Loss on early extinguishment of debt	_		5,335		_
(Gain) loss on lease abandonment	_		(509)		5,874
Loss on sale of assets, net	587		59		752
Gain on disposal, net	_		_		(2,334)
Gain on contract termination	_		_		(2,000)
Net cash provided by operating activities of discontinued operations	2,080		2,785		4,216
Change in operating assets and liabilities, net of effects of acquisitions:	_		_		_
Patient accounts receivable	(19,594)		(30,983)		(10,816)
Supplies	(480)		150		(1,669)
Receivables from affiliates, prepaids and other current assets	(1,738)		(2,748)		(2,001)
Other long-term assets	(64)		(1,004)		(200)
Accounts payable and accrued expenses	 (2,544)		2,821		841
Net cash provided by operating activities	79,132		56,826		35,674
Cash flows from investing activities	_				
Payments for acquisitions, net of cash acquired	(12,400)		(268,788)		(15,352)
Proceeds from (adjustments to) the sale of affiliates, net of cash	(443)		773		16,103
Proceeds from contract termination	_		_		1,397
Proceeds from sales (payments for purchases) of equity investments	583		565		(550)
Proceeds from the sale of property and equipment	590		353		631
Proceeds from distributions of unconsolidated affiliates	2,871		8,968		10,956
Purchases of property and equipment	(13,546)		(14,395)		(7,874)
Net cash provided by (used in) investing activities	 (22,345)		(272,524)		5,311
Cash flows from financing activities					
Proceeds from the issuance of long-term debt	15,823		483,667		45,683
Repayments of long-term debt	(19,483)		(11,028)		(6,162)
Early settlement of debt			(207,093)		_
Payments of debt issuance costs	_		(17,294)		(1,076)
Proceeds from (payments to) noncontrolling interests, net	(1,170)		224		(369)
Distributions to noncontrolling interests	(41,060)		(31,073)		(23,452)
Proceeds (payments) from stock option exercises (repurchases), net	19		42		(646)
Dividends paid	(20,009)		_		(35,700)
Net cash provided by (used in) financing activities	 (65,880)		217,445		(21,722)
Net increase (decrease) in cash	 (9,093)		1,747		19,263
Cash, beginning of year	39,549		37,802		18,539
Cash, end of year	\$ 30,456	\$	39,549	\$	37,802
Cash, end of year continuing operations	\$ 29,677	\$	38,673	\$	35,282
Cash, end of year discontinued operations	779		876		2,520
Non-cash transactions and supplemental cash flow information:					
Direct financing of property and equipment	\$ 21,283	\$	4,100	\$	13,770
Interest paid	30,048		22,551		11,295
Cash paid for income taxes, net of refunds received	3,344		8,609		7,110

Notes to Consolidated Financial Statements

(In thousands except years, units and per share amounts)

NOTE 1 - DESCRIPTION OF BUSINESS

NSH Holdco, Inc. ("NSH Holdco, Inc.") is the sole owner of National Surgical Hospitals, Inc. and Subsidiaries, d/b/a National Surgical Healthcare ("NSH" or the "Company"), which it acquired in February 2011. NSH owns and operates surgical hospitals and ambulatory surgery centers in partnership primarily with physicians. The clinical concentration of NSH's facilities is primarily in the musculoskeletal area and includes orthopedics, spine and pain management. In addition, NSH supports general, bariatric, urology, ENT, ophthalmology and plastic surgery. Certain of the Company's surgical facilities may also provide related ancillary services, including imaging and physical therapy. As of December 31, 2016, the Company owned and operated 14 surgical hospitals and eight ambulatory surgery centers throughout the United States.

NSH Holdco, Inc. is owned by Irving Place Capital, a New York-based private equity firm, and its affiliates as well as certain members of the Company's management and board of directors. NSH commenced operations in 1998.

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Management Estimates - The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect reported amounts of assets, liabilities, revenue and expenses and disclosure of contingent assets and liabilities at the date of the financial statements. These estimates and assumptions are based on management knowledge, historical trends, current events and assumptions about future events. Actual results could differ from these estimates.

Principles of Consolidation - The consolidated financial statements include all accounts of the Company and its wholly owned subsidiaries and majority-owned or controlled partnerships or limited liability companies. Ownership interests in consolidated subsidiaries held by parties other than the Company are identified and presented in the consolidated financial statements as noncontrolling interests. Consolidated net income attributable to the Company and to the noncontrolling interest are identified and presented on the face of the consolidated statements of operations; changes in ownership interests are accounted for as equity transactions. Certain transactions with noncontrolling interests are also classified within financing activities in the statement of cash flows. All significant intercompany balances and transactions have been eliminated in consolidation.

Investments in entities that the Company does not control, but in which it has a substantial ownership interest and can exercise significant influence, are accounted for using the equity method. These investments are included as investments in unconsolidated affiliates in the accompanying consolidated balance sheets. The Company's share of profits and losses from these investments is reported in equity in earnings of unconsolidated affiliates in the accompanying consolidated statements of operations.

The Company operates in one reportable business segment, the ownership and operation of surgical hospitals and ambulatory surgical centers.

Variable Interest Entities - Variable interest entities ("VIEs") are entities that, by design, either (i) lack sufficient equity to permit the entity to finance its activities independently, or (ii) have equity holders that, as a group, do not have the power to direct the activities of the entity that most significantly impact its economic performance, the obligation to absorb the entity's losses, or the right to receive the entity's residual returns. We consolidate a VIE when we are the primary beneficiary, which is the party that has both (i) the power to direct the activities that most significantly impact the VIE's economic performance and (ii) through its interests in the VIE, the obligation to absorb losses or the right to receive benefits from the VIE that could potentially be significant to the VIE.

Certain of our consolidated subsidiaries that are less than wholly owned meet the definition of VIEs. In order to determine whether we own a variable interest in a VIE, we perform qualitative analysis of the entity's design, organizational structure, primary decision makers and relevant agreements. We consolidate such VIEs if we determine that we are the primary beneficiary because (i) we have the power to direct the activities that most significantly impact the economic performance of the VIE via our rights and obligations associated with the management and operation of the VIEs' healthcare facilities, and (ii) we have the obligation, through our equity interests, to absorb losses or receive benefits that could potentially be significant to the VIE. Our loss exposure typically is limited to our equity investment in these entities.

Note that no VIE assets are subject to NSH creditors, and only one VIE liability is secured by NSH assets via a debt guarantee, which is discussed later in this footnote. Additionally, as a shareholder in the facilities, NSH is not obligated to provide financial support. The following table summarizes the carrying amount of the assets and liabilities of our material VIEs included in the Company's consolidated balance sheets (after elimination of intercompany transactions and balances):

Notes to Consolidated Financial Statements

(In thousands except years, units and per share amounts)

	Years ended December 31,				
	 2016		2015		2014
Assets					
Cash	\$ 22,915	\$	22,994	\$	18,940
Patient accounts receivable	95,853		89,085		48,436
Supplies	14,910		14,424		11,074
Property and equipment, net	142,687		131,586		90,292
Liabilities					
Accounts payable	\$ 32,001	\$	28,420	\$	17,558
Accrued expenses	27,217		24,538		14,828
Current maturities of capital leases and other long-term debt	19,867		12,028		11,094
Capital leases and other long-term debt, net, less current maturities	55,024		41,166		21,624
Deferred financing obligations	26,047		26,662		28,047

Revenue Recognition - The Company recognizes patient service revenue upon delivery of services to a patient. The Company receives a portion of its net patient service revenue from Medicare and Medicard programs and commercial insurance carriers. The Company's facilities have agreements with these third-party payors that provide for payments under various fixed prices or amounts that differ from the established rates. Net patient service revenue is reported at the estimated net realizable amounts from patients, third-party payors and others as services are rendered, including estimated adjustments under reimbursement agreements with third-party payors, certain of which are subject to audit by administering agencies. These adjustments are accrued on an estimated basis and are adjusted as needed in future periods.

Allowance for Doubtful Accounts - Accounts receivable is reduced by an allowance for amounts that could become uncollectible in the future. Substantially all of the Company's receivables relate to providing healthcare services to patients at its facilities. For most payor categories, the Company reserves 100 percent of accounts aged over 150 days from the date of service. For some payor categories in certain geographic locations, additional reserves are determined using historical collection percentages rather than the aging. The Company collects substantially all of its third-party insured receivables, which include receivables from governmental agencies.

Collections are impacted by the economic ability of patients to pay and the effectiveness of the Company's collection efforts. Significant changes in payor mix, business office operations, economic conditions or trends in federal and state governmental healthcare coverage could affect the Company's collection of accounts receivable. The process of estimating the allowance for doubtful accounts requires the Company to estimate the collectability of accounts receivable, which is primarily based on its collection history, adjusted for expected recoveries and, if available, anticipated changes in collection trends. The Company also continually reviews its overall reserve adequacy by monitoring historical cash collections as a percentage of historical net patient service revenue and aged accounts receivable by payor.

Patient service revenues from continuing operations, net of contractual allowances and discounts (but before provision for bad debts), by payor source were as follows:

		Years ended December 31,				
	2016	2015	2014			
Medicare	\$129,355	\$116,265	\$81,298			
Medicaid	16,233	14,310	5,223			
Managed care and other third-party payors	435,973	377,119	230,467			
Self-pay (including co-pays and deductibles)	8,385	6,364	5,304			
Total	\$589,946	\$514,058	\$322,292			

Management Fees and Other Revenue - The Company recognizes management fee revenue for services provided under contractual agreements with consolidated and unconsolidated affiliates. Amounts recognized as revenue are in accordance with contract terms. Management fees from unconsolidated affiliates for the years ended December 31, 2016, 2015 and 2014 amounted to \$3,295, \$3,595 and \$4,204, respectively, and are included in management fees and other revenue in the accompanying consolidated statements of operations. All such revenue from consolidated affiliates is eliminated in consolidation.

The Company earns rental income by leasing available space at its facilities to physicians and other healthcare providers. Rental income of \$3,012, \$3,598 and \$53 was recognized for the years ended December 31, 2016, 2015 and 2014, respectively, and is included in management fees and other revenue in the accompanying consolidated statements of operations.

Notes to Consolidated Financial Statements

(In thousands except years, units and per share amounts)

Other Income - Under certain provisions of the American Recovery and Reinvestment Act of 2009 ("ARRA"), federal incentive payments are available to hospitals, physicians and certain other professionals ("Providers") when they adopt, implement or upgrade ("AIU") certified electronic health record ("EHR") technology or become "meaningful users," as defined under ARRA, of EHR technology in ways that demonstrate improved quality, safety and effectiveness of care. Providers can become eligible for annual Medicare incentive payments by demonstrating meaningful use of EHR technology in each period over four periods. The Company's first measurement period began July 2013. Medicaid providers can receive their initial incentive payment by satisfying AIU criteria, but must demonstrate meaningful use of EHR technology in subsequent years in order to qualify for additional payments. Hospitals may be eligible for both Medicare and Medicaid EHR incentive payments. Hospitals that are meaningful users under the Medicare EHR incentive payment program are deemed meaningful users under the Medicaid EHR incentive payment program and do not need to meet additional criteria imposed by a state. Medicaid EHR incentive payments to Providers are 100 percent federally funded and administered by the states. Before a state may offer EHR incentive payments, the state must submit and the Centers for Medicare and Medicaid Services ("CMS") must approve the state's incentive plan.

The Company recognizes Medicare EHR incentive payments in the consolidated statements of operations when: (1) the specified meaningful use criteria are met; and (2) contingencies in estimating the amount of the incentive payments to be received are resolved. The Company recognizes Medicaid EHR incentive payments for the first payment year when: (1) CMS approves a state's EHR incentive plan; and (2) a hospital acquires certified EHR technology (i.e., when AIU criteria are met). Medicaid EHR incentive payments for subsequent payment years are recognized in the period during which the specified meaningful use criteria are met.

Certain of the Company's hospitals satisfied the CMS AIU and/or meaningful use criteria during fiscal years 2016, 2015 and 2014. As a result, the Company recognized \$2,728, \$4,253 and \$6,808 of Medicare and Medicaid EHR incentive payments, based on available cost report information, as other income in the accompanying consolidated statements of operations for the years ended December 31, 2016, 2015 and 2014, respectively. Upon filing each year's cost report in the subsequent fiscal year, the Company modified its estimates of 2015, 2014 and 2013 EHR incentive payments and recognized an increase of \$428 and reductions of \$478 and \$244, respectively, in the meaningful use receivable. These adjustments are recognized as other income or expense and are included with or netted against meaningful use revenue for the years ended December 31, 2016, 2015 and 2014, respectively.

Also included in other income in the accompanying consolidated statement of operations for the year ended December 31, 2015 is \$95 related to the execution of a management subcontract at one of the Company's subsidiaries.

Debt Issuance Costs and Original Issue Discount - The Company capitalizes third-party costs associated with the issuance of debt instruments, and costs paid to lenders in connection with the issuance of debt are accounted for as original issue discount. Capitalized third-party costs and the original issue discount are netted against the carrying amount of the obligation on the balance sheet, and both are amortized on a straight-line basis, which approximates the effective interest method, over the term of the debt agreements. Refer to Note 9 for information on the Company's debt obligations.

Income Taxes - Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company records penalties and interest incurred as other operating expenses and interest expense, respectively, in the accompanying consolidated statements of operations.

Uncertain tax positions are recognized and measured under the applicable accounting standards. These provisions require that the impact of a tax position be recognized if that position is more likely than not of being sustained on audit, based solely on the technical merits of the position. As of December 31, 2016 and 2015, the Company had \$0 and \$98, respectively, recorded for liabilities related to uncertain tax positions.

The Company and its subsidiaries are subject to U.S. federal income tax as well as income tax of multiple-state jurisdictions. The Company is no longer subject to examination by U.S. federal taxing authorities, and for all state income taxes, for years before January 1, 2012. The Company does not expect the total amount of unrecognized tax benefits to significantly increase or decrease in the next twelve months.

Cash - The Company considers all balances held to be highly liquid and available upon request.

Patient Accounts Receivable - Patient accounts receivable are stated at net realizable value. The Company does not require collateral for its accounts receivable, which is consistent with industry practice.

Supplies - Supplies, comprised principally of medical supplies, drugs and gases, are stated at the lower of cost (weighted-average method) or market.

Property and Equipment - Property and equipment are stated at cost. Property and equipment under capital leases are stated at the lower of the present value of the minimum lease payments or the fair value of the underlying asset. Depreciation and amortization expense is computed using the straight-line method over the estimated useful lives of the asset or, if shorter, the terms of the leases for the related assets. The estimated useful lives are 40 years for buildings, 7 to 10 years for medical and surgical equipment and 5 to 10 years for furniture and fixtures. Depreciation for software development is recognized over a useful life of 5 years.

Notes to Consolidated Financial Statements

(In thousands except years, units and per share amounts)

Goodwill and Intangible Assets - Goodwill represents the excess value of an acquired entity over the amounts assigned to assets acquired and liabilities assumed in a business combination. Intangible assets primarily represent amounts assigned to certificates of need, tradenames, non-competition agreements, specific management contracts and other licenses.

Long-Lived Assets - The carrying value of long-lived assets, including intangible assets with finite lives, is reviewed for impairment if facts and circumstances, including changes in current economic and market conditions and the operating performance of the investments, suggest that the carrying value of the asset held may not be recoverable based on the undiscounted future cash flows of the asset. In this situation, the carrying value of the asset will be reduced to its estimated fair value. No impairment of long-lived assets was identified in 2016, 2015 or 2014.

Noncontrolling Interests - redeemable - Ownership interests in consolidated subsidiaries held by parties other than the Company are identified and generally presented in the consolidated financial statements separate from the Company's equity. However, in instances in which certain redemption features that are not solely within the control of the Company are present, classification of noncontrolling interests outside of permanent equity is required. In certain circumstances, the partnership and operating agreements for the Company's surgical facilities provide that the facilities will purchase all of the physicians' ownership if certain adverse regulatory events occur, such as it becoming illegal for the physicians to own an interest in a surgical facility, refer patients to a surgical facility or receive cash distributions from a surgical facility. The noncontrolling interests for these facilities are recorded as noncontrolling interests - redeemable and reported outside of stockholders' equity in the consolidated balance sheets.

		Noncontrolling
	Inte	rests - redeemable
Balance: December 31, 2014	\$	98,642
Net income		19,397
Distributions to noncontrolling interests		(20,635)
Change in noncontrolling interests from acquisitions, deconsolidation and disposal, net		29,332
Change in noncontrolling interests from other activity, net		435
Balance: December 31, 2015	\$	127,171
Net income		16,740
Distributions to noncontrolling interests		(20,377)
Change in noncontrolling interests from other activity, net		(1,453)
Balance: December 31, 2016	\$	122,081

Off-Balance-Sheet Risk and Concentration of Credit Risk - Financial instruments, which potentially subject the Company to concentrations of credit risk, consist principally of cash and patient accounts receivable. The majority of the Company's funds at December 31, 2016 were maintained with financial institutions in amounts in excess of federally insured limits. The Company receives payments for services rendered from federal and state agencies (under the Medicare and Medicaid programs), managed care health plans, commercial insurance companies, employers and patients. Revenues and receivables from government agencies are significant to operations, but the Company does not believe there are significant credit risks associated with these government agencies. The Company does not believe there are any other significant concentrations of revenues from any particular payor that would subject the Company to any significant credit risks in the collection of accounts receivable.

The Company grants credit without collateral to its patients, most of whom are local residents and are insured under third-party payor agreements. The Company believes that the concentration of credit risk with respect to patient accounts receivable is limited due to the large number of patients comprising the Company's patient base and their dispersion across many different insurance companies, health maintenance and preferred provider organizations and other third-party payors and patients.

Notes to Consolidated Financial Statements

(In thousands except years, units and per share amounts)

The mix of receivables from patients and third-party payors from continuing operations is as follows:

	At December 31,	
	2016	2015
Medicare	21 %	21 %
Medicaid	4	4
Blue Cross/Blue Shield	25	22
Managed Care	20	21
Worker's Compensation	8	9
Self-pay	6	8
Other third-party payors and patients	16	15
	100 %	100 %

For all years presented, the Company had no financial instruments with off-balance-sheet risk.

Debt Guarantees - As of December 31, 2016 and 2015, the Company had \$14,350 and \$14,896, respectively, of debt guarantees for a consolidated affiliate.

Stock-Based Compensation - The Company records compensation expense associated with stock options in accordance with Accounting Standards Codification ("ASC") 718, Compensation - Stock Compensation. Refer to Note 12 for a summary the significant assumptions used in determining the underlying fair value of options and disclosures.

Results from Unconsolidated Affiliates - The Company invests in several facilities in which the Company has significant influence but does not have control. The equity method is used to account for these investments. The majority of these investments are partnerships or limited liability companies, which require the associated tax benefit or expense to be recorded by the partners or members. As of December 31, 2016, 2015 and 2014, the Company has evaluated the investments and determined there is no impairment.

Summarized financial and other information for the Company's equity method investments on a combined basis was as follows (amounts are in thousands, except number of facilities, and reflect the results on an aggregated basis):

		Years ended December 31,	
	2016	2015	2014
Number of facilities	4	5	6
Range of ownership percentages	20 - 41%	5 - 43%	9 - 50%
Selected operating results:			
Net patient service revenue	\$71,909	\$77,144	\$133,817
Net income	9,467	8,593	29,284
Selected balance sheet information:			
Assets	22,627	33,107	56,706
Liabilities	13,289	21,663	21,802

Equity in earnings of \$3,713, which represents the contribution of two previously unconsolidated affiliates acquired in the prior year, is included in the accompanying consolidated statement of operations for the year ended December 31, 2015.

NOTE 3 - RECENT ACCOUNTING PRONOUNCEMENTS

Several Accounting Standards Updates ("ASUs") recently issued by the Financial Accounting Standards Board could have an impact on the Company's financial reporting. These ASUs are described below. Of those listed, ASUs 2014-12, 2015-02, 2015-03, 2015-15 and 2015-17 were adopted in 2016. The rest are effective for the Company beginning in 2017 or after.

ASU 2014-09 "Revenue from Contracts with Customers" affects any entity that either enters into contracts with customers to transfer goods or services or enters into contracts for the transfer of nonfinancial assets unless those contracts are within the scope of other standards, such as insurance or lease contracts. This ASU will supersede current revenue recognition requirements and most industry-specific guidance. The core principle of the guidance, which becomes effective in 2018, is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those specific goods or services. The Company has not yet determined the impact this standard will have on the consolidated financial statements, if any.

Notes to Consolidated Financial Statements

(In thousands except years, units and per share amounts)

ASU 2014-12 "Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period" requires that a performance target that affects vesting and that could be achieved after the requisite service period is treated as a performance condition. An entity should recognize compensation cost in the period in which it becomes probable that the performance target will be achieved and should represent the compensation cost attributable to the periods for which the requisite service has already been rendered. If the performance target becomes probable of being achieved before the end of the requisite service period, the remaining unrecognized compensation cost should be recognized prospectively over the remaining requisite service period. The total amount of compensation cost recognized during and after the requisite service period should reflect the number of awards that are expected to vest and should be adjusted to reflect those awards that ultimately vest. This ASU became effective in 2016 and its adoption did not have a significant impact on the Company's consolidated financial statements.

ASU 2015-02 "Amendments to the Consolidation Analysis" amends and revises ASC 810, *Consolidation*, by making changes to both the variable interest model and the voting model. The ASU is effective for public business entities in 2016 and impacts all reporting entities involved with limited partnerships by requiring a reevaluation of these entities for consolidation. Its adoption had no impact on the Company's consolidated financial statements. However, additional disclosure was required and has been included.

ASU 2015-03 "Simplifying the Presentation of Debt Issuance costs" intends to simplify the presentation of debt issuance costs by requiring debt issuance costs to be presented on the balance sheet as a direct deduction from the carrying amount of the debt liability, consistent with debt discounts. The ASU is effective in 2016 and affects all companies and other organizations that have outstanding debt. Its adoption did not have a significant impact on the Company's consolidated financial statements.

ASU 2015-15 "Presentation and Subsequent Measurement of Debt Issuance Costs Associated with Line-of-Credit Arrangements" amends and revises ASU 2015-03 by adding clarification on the presentation and subsequent measurement of debt issuance costs related to line-of-credit arrangements. The ASU is effective in 2016 and affects all companies and other organizations that have a line-of-credit arrangement. Its adoption did not have a significant impact on the Company's consolidated financial statements.

ASU 2015-16 "Business Combinations - Simplifying the Accounting for Measurement-Period Adjustments" allows the ability

to recognize, in current period earnings, any changes in provisional amounts during the measurement period after the closing of an acquisition, instead of restating prior periods for these changes. This ASU became effective in 2016 and had no impact on the Company's consolidated financial statements.

ASU 2015-17 "Balance Sheet Classification of Deferred Taxes" intends to simplify the presentation of deferred income taxes by requiring that deferred tax liabilities and assets be classified as noncurrent on the balance sheet. The ASU is effective and was adopted by the Company beginning with calendar year 2017.

ASU 2016-02 "Leases" will require lessees to recognize a lease liability and right-of-use asset at commencement date for all leases with a term longer than twelve months. The ASU affects all companies and other organizations that lease assets. It becomes effective for public business entities in 2019. The Company has not yet determined the impact this standard will have on the consolidated financial statements.

ASU 2016-07 "Investments- Equity Method and Joint Ventures" allows investments that now meet equity method treatment that were previously accounted for under a different method to apply the equity method prospectively from the date the investment qualifies for equity method treatment. The ASU is effective and was adopted by the Company beginning with calendar year 2017.

ASU 2016-09 "Improvements to Employee Share-Based Payment Accounting" simplifies the accounting for share-based payments including the income tax consequences, classification of certain awards and treatment of forfeitures. The ASU is effective and was adopted by the Company beginning with calendar year 2017.

NOTE 4 - ACQUISITIONS

In the current and prior years, the Company acquired multiple surgical hospitals, surgery centers and ancillary businesses as part of its long-term growth strategy. The Company believes the goodwill recorded as a result of the transactions reflect the reputations of the physician practices and referral networks acquired as well as the synergistic benefits of the Company's expertise to improve operations with its specialized approach to quality healthcare.

In October 2016, one of the Company's subsidiaries acquired an ancillary services business in an existing market for \$12,400. The acquisition was accounted for as a business acquisition in accordance with the provisions of ASC 805, *Business Combinations*, whereby the purchase price is allocated to the acquired assets at fair value. Goodwill recorded as a result of the transaction amounted to \$10,982, all of which is deductible for tax purposes.

In connection with the purchase price allocation, the Company estimated the fair values of the acquired long-lived assets with the assistance of a third-party valuation firm. In valuing these assets, the fair values were based upon, but not limited to, a consideration of the cost approach,

Notes to Consolidated Financial Statements

(In thousands except years, units and per share amounts)

whereby value is determined based on the cost to recreate or replace the subject asset. The allocation of the purchase price, as reflected at the transaction date, is as follows:

Property and equipment	\$1,418
Goodwill	10,982
Net assets acquired	\$12,400

Transaction related expenses due to the acquisition were immaterial, and all were expensed as incurred in corporate, general and administrative expenses in the accompanying consolidated statement of operations for the year ended December 31, 2016. Total revenue of \$1,181 and operating income of \$1,007 are included in the accompanying consolidated statement of operations for the year ended December 31, 2016.

In September 2015, the Company gained control of a previously unconsolidated surgery center through an amendment to voting rights. No consideration was exchanged. Prior to gaining control, the Company accounted for its 43 percent ownership interest in the facility under the equity method of accounting. The change in control qualified as a business combination achieved in stages under ASC 805, *Business Combinations*. In accordance with the guidance, the preexisting equity interest was remeasured at fair value when control was obtained and a resulting gain of \$415 is recognized in gain on acquisitions in the accompanying consolidated statement of operations for the year ended December 31, 2015. Additionally, the entity's assets and liabilities, including all noncontrolling interests, were recognized at fair value at the acquisition date. Goodwill recorded as a result of the consolidation amounted to \$5,112, of which \$0 is deductible for tax purposes. The gain from acquisition was calculated as follows:

Fair value of preexisting equity interest	\$2,828
Book value of preexisting equity interest	2,413
Gain recognized	\$415

The Company estimated the fair values of the acquired long-lived and intangible assets, assumed liabilities and noncontrolling interests with the assistance of a third-party valuation firm. In valuing these assets and liabilities, the fair values were based upon a combination of three approaches; income approach, whereby value is estimated based on the present value of expected future economic benefits; market approach, whereby value is established by examining the value of similar assets in a free and open market or through the analysis of recent sales or offerings of comparable assets; and cost approach. The allocation of the purchase price, which is equal to the fair value of the preexisting equity interest, is as follows:

Cash	\$515
Patient accounts receivable	548
Supplies	359
Prepaid expenses and other current and long-term assets	122
Property and equipment	5,270
Goodwill	5,112
Accounts payable	(225)
Accrued expenses and other current liabilities	(225)
Current maturities of capital leases and other long-term debt	(102)
Capital leases and other long-term debt, net, less current maturities	(4,061)
Deferred tax liability	(767)
Noncontrolling interests	(3,718)
Net assets acquired	\$2,828

Transaction related expenses due to the acquisition were immaterial, and all were expensed as incurred in corporate, general and administrative expenses in the accompanying consolidated statement of operations for the year ended December 31, 2015.

In June 2015, the Company acquired a hospital holding company for total cash consideration of \$208,968, net of acquired cash of \$1,067. The holding company owns all economic and other rights related to two critical access hospitals, seven physical therapy clinics, two imaging centers and eight rural health clinics as well as 51 percent of the economic and other rights related to a surgical hospital and an ambulatory surgery center. The acquisition was accounted for as a business acquisition in accordance with the provisions of ASC 805, *Business Combinations*, whereby the purchase price is allocated to the acquired assets and liabilities at fair value. Goodwill recorded as a result of the transaction amounted to \$235,830, of which \$132,608 is deductible for tax purposes.

Notes to Consolidated Financial Statements

(In thousands except years, units and per share amounts)

In connection with the purchase price allocation, the Company estimated the fair values of the acquired long-lived and intangible assets, assumed liabilities and noncontrolling interests with the assistance of a third-party valuation firm. In valuing these assets and liabilities, the fair values were based upon a combination of the income, market and cost approaches. The allocation of the purchase price, as reflected at the transaction date, is as follows:

Cash	\$1,067
Patient accounts receivable	15,848
Supplies	2,734
Prepaid expenses and other current assets	1,386
Property and equipment	29,421
Goodwill	235,830
Intangible assets	96,010
Accounts payable	(2,986)
Accrued expenses	(6,815)
Current maturities of capital leases and other long-term debt	(197)
Capital leases and other long-term debt, less current maturities	(1,863)
Noncontrolling interests	(160,400)
Net assets acquired	\$210,035

The Company incurred \$1,856 of transaction related expenses due to the acquisition, all of which were expensed as incurred in corporate, general and administrative expenses in the accompanying consolidated statement of operations for the year ended December 31, 2015.

In June 2015, the Company purchased an additional 32.5 percent and gained control of a previously unconsolidated surgical hospital for cash consideration of \$56,080, net of acquired cash of \$482. Prior to the transaction, the Company accounted for its 50 percent ownership interest in the hospital under the equity method of accounting. The transaction qualified as a business combination achieved in stages under ASC 805, *Business Combinations*. In accordance with the guidance, the preexisting equity interest was remeasured at fair value when control was obtained and a resulting gain of \$62,398 is recognized in gain on acquisitions in the accompanying consolidated statement of operations for the year ended December 31, 2015. Additionally, the hospital's assets and liabilities, including all noncontrolling interests, were recognized at fair value at the acquisition date. Goodwill recorded as a result of the transaction amounted to \$147,620, of which \$55,387 is deductible for tax purposes. The gain from acquisition was calculated as follows:

Fair value of preexisting equity interest	\$78,317
Book value of preexisting equity interest	15,919
Gain recognized	\$62,398

The Company estimated the fair values of the acquired long-lived and intangible assets, assumed liabilities and noncontrolling interests with the assistance of a third-party valuation firm. In valuing these assets and liabilities, the fair values were based upon a combination of the income, market and cost approaches. The allocation of the purchase price, which is composed of the cash consideration and fair value of the preexisting equity interest, is as follows:

Notes to Consolidated Financial Statements

(In thousands except years, units and per share amounts)

Cash	\$482
Patient accounts receivable	12,559
Supplies	1,205
Prepaid expenses and other current and long-term assets	2,708
Property and equipment	12,791
Goodwill	147,620
Intangible assets	6,800
Accounts payable	(5,436)
Accrued expenses	(3,860)
Current maturities of capital leases and other long-term debt	(1,641)
Capital leases and other long-term debt, less current maturities	(10,796)
Deferred tax liability	(1,665)
Noncontrolling interests	(25,888)
Net assets acquired	\$134,879

Transaction related expenses due to the acquisition were immaterial, and all were expensed as incurred in corporate, general and administrative expenses in the accompanying consolidated statement of operations for the year ended December 31, 2015.

In October 2014, the Company gained control of a previously unconsolidated surgical hospital for cash consideration of \$587, net of acquired cash of \$163. Prior to the transaction, the Company accounted for its 49 percent ownership interest in the hospital under the equity method of accounting. The transaction qualified as a business combination achieved in stages under ASC 805, *Business Combinations*. In accordance with the guidance, the preexisting equity interest was remeasured at fair value when control was obtained and a resulting gain of \$4,306 is recognized in gain on acquisitions in the accompanying consolidated statement of operations for the year ended December 31, 2014. Additionally, the hospital's assets and liabilities, including all noncontrolling interests, were recognized at fair value at the acquisition date. No goodwill was recorded as a result of the transaction. The gain from acquisition was calculated as follows:

Fair value of preexisting equity interest	\$3,664
Book value of preexisting equity interest	(642)
Gain recognized	\$4,306

The Company estimated the fair values of the acquired long-lived and intangible assets, assumed liabilities and noncontrolling interests with the assistance of a third-party valuation firm. In valuing these assets and liabilities, the fair values were based upon a combination of the income, market and cost approaches. The allocation of the purchase price, which is composed of the cash consideration and fair value of the preexisting equity interest, is as follows:

Cash	\$163
Patient accounts receivable	2,955
Supplies	890
Other current assets	470
Property and equipment	12,204
Accounts payable	(2,587)
Accrued expenses and other current liabilities	(2,803)
Long-term debt and capital leases	(1,691)
Other long-term liabilities	(1,374)
Noncontrolling interests	(3,813)
Net assets acquired	\$4,414

In August 2014, one of the Company's subsidiaries acquired an ancillary services business in an existing market for \$800. The acquisition was accounted for as a business acquisition in accordance with the provisions of ASC 805, *Business Combinations*, whereby the purchase price is allocated to the acquired assets and liabilities at fair value. As a result of the transaction, a gain of \$304 is recognized in gain on acquisitions in the accompanying consolidated statement of operations for the year ended December 31, 2014.

Notes to Consolidated Financial Statements

(In thousands except years, units and per share amounts)

In connection with the purchase price allocation, the Company estimated the fair values of the acquired long-lived assets with the assistance of a third-party valuation firm. In valuing these assets, the fair values were based upon, but not limited to, a consideration of the market and cost approaches. The allocation of the purchase price, as reflected at the transaction date, is as follows:

Property and equipment	\$1,104
Gain	(304)
Consideration paid	\$800

In May 2014, the Company acquired a 40 percent ownership interest in a surgical center for total cash consideration of \$13,965, net of acquired cash of \$262. The acquisition was accounted for as a business acquisition in accordance with the provisions of ASC 805, *Business Combinations*, whereby the purchase price is allocated to the acquired assets and liabilities at fair value. Goodwill recorded as a result of the transaction amounted to \$28,776, of which \$16,334 is deductible for tax purposes.

In connection with the purchase price allocation, the Company estimated the fair values of the acquired long-lived and intangible assets, assumed liabilities and noncontrolling interests with the assistance of a third-party valuation firm. In valuing these assets and liabilities, the fair values were based upon, but not limited to, a consideration of the market and cost approaches. The allocation of the purchase price, as reflected at the transaction date, is as follows:

Cash	\$262
Patient accounts receivable	2,471
Supplies	137
Deferred tax asset	314
Property and equipment	583
Goodwill	28,776
Intangible assets	129
Accounts payable	(228)
Accrued expenses	(234)
Long-term debt and capital leases	(443)
Noncontrolling interests	(17,540)
Net assets acquired	\$14,227

In October 2014, the Company purchased an additional 11 percent ownership interest in the surgical center for \$3,912. The transaction was funded with a short-term note that was satisfied in the first quarter of 2015. The purchase increased the Company's total ownership interest in the surgery center to 51 percent and was accounted for as an equity transaction pursuant to the provisions in ASC 810, *Consolidation*.

NOTE 5 - DECONSOLIDATIONS

In July 2015, the Company effectively sold a 44.85 percent ownership interest in a previously consolidated surgical hospital for combined cash consideration of \$1,045. The transaction reduced the Company's ownership interest in the hospital to 20.4 percent and resulted in the loss of control over the entity. The carrying amounts of the hospital's assets and liabilities were removed from the consolidated balance sheet, the retained ownership interest was recognized at fair value and the resulting gain is recognized in gain on deconsolidation in the accompanying consolidated statement of operations for the year ended December 31, 2015.

The calculation of the gain recognized through the transaction is as follows:

Fair value of consideration received	\$1,045
Fair value of retained noncontrolling investment in the hospital	475
Carrying amount of noncontrolling interest in the hospital	1,490
Less:	
Carrying amount of the hospital's assets and liabilities	(1,683)
Gain recognized	\$1,327

Included in the carrying amount of the hospital's assets in the table above is an allocation of goodwill in the amount of \$1,727; such amount was determined based on the fair value of the surgical hospital relative to the fair value of the Company's full enterprise prior to the sale.

Notes to Consolidated Financial Statements

(In thousands except years, units and per share amounts)

The Company estimated the fair value of the retained ownership interest in the hospital with the assistance of a third-party valuation firm. The estimate of the hospital's value was based upon the income approach, whereby the value of an asset is determined based on the present value of its expected future economic benefits. The remaining investment in the entity is accounted for under the equity method of accounting.

NOTE 6 - DIVESTITURES

In November 2014, the Company and the minority interest owners of a surgical hospital completed the sale of the hospital's tangible net assets, exclusive of certain working capital accounts, to a third party for total consideration of \$19,854. The sale of the tangible net assets of the surgical hospital constituted a sale of a business under ASC 350, *Intangibles-Goodwill and Other*. Consideration consisted of (i) cash proceeds of \$16,103, of which \$379 was used to pay legal expenses and other closing costs, (ii) an escrow fund of \$2,675 which will be released in accordance with the terms of the sale agreement and (iii) the assumption of \$1,076 of the surgical hospital's debt. The Company and the minority holders had owned 51 percent and 49 percent, respectively, of the surgical hospital prior to the sale. Distributions to noncontrolling interests related to the sales proceeds were \$7,704.

The carrying amount of the assets sold in this transaction was approximately \$5,861. In addition, goodwill of \$11,280 was written off in connection with the divestiture; such amount was determined based on the fair value of the surgical hospital sold relative to the fair value of the Company's full enterprise prior to the sale. Discontinued operations in the consolidated statement of operations for the year ended December 31, 2014 includes a net gain of \$2,334 as a result of the sale. Of this amount, a net loss before taxes of \$4,337 was attributable to NSH and a gain before taxes of \$6,671 was attributable to noncontrolling interests.

In conjunction with the sale discussed above, the Company agreed to terminate its management contract with the surgical hospital in exchange for a payment of \$2,000, of which \$603 is being held in escrow and will be released in accordance with the terms of the termination agreement. The gain of \$2,000 is entirely attributable to NSH and is included in discontinued operations in the consolidated statement of operations for the year ended December 31, 2014.

The components of the net assets of the discontinued operations were as follows:

	At Decen	At December 31,		
	2016	2015		
Assets				
Cash	\$779	\$876		
Other current assets	0	2,320		
Total current assets	779	3,196		
Other long-term assets	1,378	1,378		
Total assets	\$2,157	\$4,574		
Liabilities				
Accounts payable and accrued expenses	\$216	\$107		
Income taxes payable	129	129		
Total current liabilities	345	236		
Deferred tax liability	338	687		
Total net assets	\$1,474	\$3,651		

Notes to Consolidated Financial Statements

(In thousands except years, units and per share amounts)

The statements of operations for the discontinued operations were as follows:

	Years ended December 31,		
	2016	2015	2014
Revenues			
Patient service revenues (net of contractual allowances and discounts)	\$395	\$350	\$29,523
Less: Provision for bad debts	0	0	(1,840)
Net patient service revenue	395	350	27,683
Costs and Expenses			
Salaries, supplies and other operating expenses	160	0	26,619
Depreciation and amortization	0	0	1,605
Total operating expenses	160	0	28,224
Operating income (loss)	235	350	(541)
Other income (expense)			
Interest expense, net	0	0	(59)
Other income	0	0	785
Gain on disposal	0	17	2,334
Gain on contract termination	0	0	2,000
Total other income, net	0	17	5,060
Income before taxes	235	367	4,519
income before taxes	233	307	4,313
Income tax benefit (expense)	(526)	920	(2,981)
Net income (loss)	\$(291)	\$1,287	\$1,538
Net income (loss) attributable to NSH	\$(146)	\$671	\$(5,224)
Net income (loss) attributable to noncontrolling interests	(145)	616	6,762

NOTE 7 - GOODWILL AND INTANGIBLE ASSETS

The changes in the carrying amount of goodwill for the years ended December 31, 2016 and 2015 are as follows:

	At December 31,		
	2016	2015	
Balance, beginning of year	\$654,552	\$267,717	
Goodwill acquired as part of acquisitions	10,982	388,562	
Goodwill allocated to deconsolidations	0	(1,727)	
Balance, end of year	\$665,534	\$654,552	

The Company evaluates goodwill for impairment at least on an annual basis and more frequently if certain indicators are encountered. Goodwill is tested at the reporting unit level, with the fair value of the reporting unit compared to its carrying amount, including goodwill. If the fair value of a reporting unit exceeds its carrying amount, goodwill of the reporting unit is not considered to be impaired. The Company's methodology utilizes a discounted cash flow model and a market approach to estimate fair value. The fair value analysis requires significant judgments and estimates to be made by management. Changes in market conditions, among other factors, may have an impact on these estimates, which may require future adjustments to the carrying value of goodwill. Based upon the comparison of the estimated fair value to carrying value, management has made no adjustments for impairment in 2016, 2015 or 2014.

Notes to Consolidated Financial Statements

(In thousands except years, units and per share amounts)

Intangible assets, net were as follows:

At December 31, 2016

	Gross Carrying Value	Accumulated Amortization	Net Carrying Value	Estimated Remaining Useful Life (Years)
Certificates of need - 2015 Acquisitions	\$79,680	0	\$79,680	Indefinite
Certificates of need - Pre-2015	647	110	537	31
Tradenames	17,880	1,887	15,993	13
Non-compete agreements	5,250	1,666	3,584	3
Management contracts	3,546	1,857	1,689	10
Licenses	174	32	142	30
Total	\$107,177	\$5,552	\$101,625	

At December 31, 2015

	Gross Carrying Value	Accumulated Amortization	Net Carrying Value	Estimated Remaining Useful Life (Years)
Certificates of need - 2015 Acquisitions	\$79,680	0	\$79,680	Indefinite
Certificates of need - Pre-2015	647	90	557	31
Tradenames	17,880	695	17,185	14
Non-compete agreements	5,250	617	4,633	4
Management contracts	3,546	1,543	2,003	10
Licenses	182	28	154	31
Total	\$107,185	\$2,973	\$104,212	

The amortization of intangible assets, substantially all from continuing operations, totaled \$2,581, \$4,852 and \$472 for the years ended December 31, 2016, 2015 and 2014, respectively, and is included in depreciation and amortization expense in the accompanying consolidated statements of operations. During 2015, the Company derecognized management contracts and licenses with a net carrying amount of \$3,088. This amount is included in depreciation and amortization in the accompanying consolidated statement of operations for the year ended December 31, 2015. Annual amortization expense on intangible assets recorded as of December 31, 2016 is estimated to be \$2,581 for the years 2017 through 2019, \$1,867 in year 2020 and \$1,265 in year 2021.

The amount of goodwill and intangible assets that are deductible for tax purposes totaled \$272,535 and \$297,502 at December 31, 2016 and 2015, respectively.

Notes to Consolidated Financial Statements

(In thousands except years, units and per share amounts)

NOTE 8 - PROPERTY AND EQUIPMENT, NET

Property and equipment consists of the following:

	At Decen	At December 31,		
	2016	2015		
Land and land improvements	\$6,796	\$6,796		
Buildings and building improvements	97,491	96,119		
Medical and surgical equipment	78,989	76,594		
Furniture and fixtures	32,878	39,743		
Leasehold improvements	42,092	25,901		
Construction in progress	4,819	5,031		
Total property and equipment, at cost	263,065	250,184		
Less accumulated depreciation and amortization	(70,598)	(64,872)		
Property and equipment, net	\$192,467	\$185,312		

Included in property and equipment is capitalized leased property and equipment that aggregated \$9,502 and \$9,574, net of accumulated depreciation of \$2,307 and \$982, at December 31, 2016 and 2015, respectively. Additionally, property and equipment capitalized under sale-leaseback accounting aggregated \$36,172 and \$38,202, net of accumulated depreciation of \$7,411 and \$4,814, at December 31, 2016 and 2015, respectively.

Depreciation expense from continuing operations was \$28,247, \$26,913 and \$15,612 for 2016, 2015 and 2014, respectively, and is included in depreciation and amortization in the accompanying consolidated statements of operations.

NOTE 9 - DEBT AND LEASE COMMITMENTS

Long-term debt and obligations under capital leases consist of the following:

	At December 31,		
	2016	2015	
First Lien Term Loan, interest at LIBOR plus 3.50% with a LIBOR			
floor of 1.00% due through 2022	\$359,525	\$363,175	
Second Lien Note, interest at LIBOR plus 9.00% with a LIBOR			
floor of 1.00% due through 2023	105,000	105,000	
Installment notes payable with interest rates ranging from			
2.21% to 6.80% due monthly through 2025	67,045	44,767	
Obligations under capital leases, interest rates ranging from			
0.35% to 12.00%, due through 2029	10,079	10,158	
Borrowings under lines of credit with interest rates ranging from			
prime to 5.00%	1,608	2,534	
Total long-term debt and capital leases	543,257	525,634	
Less:			
Unamortized discount and deferred issuance costs	(13,914)	(16,558)	
Current portion of long-term debt and capital leases	(23,517)	(16,103)	
Long-term debt and capital leases, less current portion	\$505,826	\$492,973	

Credit agreement - In June 2015, the Company entered into a First Lien Credit Agreement, which provided funding of up to \$405,000, and a Second Lien Notes Purchase Agreement, which provided funding of \$105,000.

The First Lien Credit Agreement consists of a \$365,000 Term Loan Commitment (the "First Lien Term Loan") and a \$40,000 Revolving Loan Commitment (the "Revolving Loan"). The First Lien Term Loan matures in June 2022 and had an outstanding balance of \$359,525 and \$363,175 at December 31, 2016 and 2015, respectively. The Revolving Loan is available until June 2020 and had an availability of \$40,000 at December 31, 2016 and 2015. The Company pays a 0.5% commitment fee on the average daily unused portion of the Revolving Loan. The Second Lien Notes Purchase Agreement consists of a \$105,000 Note (the "Second Lien Note"), which matures in June 2023 and had an outstanding balance

Notes to Consolidated Financial Statements

(In thousands except years, units and per share amounts)

of \$105,000 at December 31, 2016 and 2015. Accrued interest on the outstanding First Lien Term Loan and Second Lien Note was \$149 and \$75 at December 31, 2016 and 2015, respectively, and is included in accrued expenses on the accompanying consolidated balance sheets.

The funds drawn on the First Lien Term Loan and the Second Lien Note were used to fund acquisitions and repay the former secured debt. As a result of the repayment, the Company recognized a \$5,117 loss on the early extinguishment of debt on the accompanying consolidated statement of operations for the year ended December 31, 2015. The loss represented a write-off of \$3,879 relating to unamortized original issue discount and \$1,238 relating to unamortized deferred loan costs.

Deferred Debt Issuance Costs and Original Issue Discount - At December 31, 2016 and 2015, the Company had deferred debt issuance costs, net, in the amount of \$2,734 and \$3,246, respectively, which is netted against the carrying amount of long-term debt and capital leases on the accompanying consolidated balance sheets. Amortization expense for debt issuance costs was \$512, \$469 and \$321 for the years ended December 31, 2016, 2015 and 2014, respectively, and is included in interest expense in the accompanying consolidated statements of operations.

At December 31, 2016 and 2015, the Company had original issue discount, net, in the amount of \$11,179 and \$13,312, respectively, which is netted against the carrying amount of long-term debt and capital leases on the accompanying consolidated balance sheets. Amortization expense for original issue discount costs was \$2,133, \$1,682 and \$1,029 for 2016, 2015 and 2014, respectively, and is included in interest expense in the accompanying consolidated statements of operations.

Facility Lines of Credit - Certain of the Company's subsidiaries have lines of credit available with a total borrowing capacity of \$9,600, of which \$7,992 was available at December 31, 2016. Interest rates range from 3.75% to 5.00%, and the lines are collateralized by assets of the individual operating facilities.

Lease Commitments - The Company leases corporate office space, operating facilities and various equipment under operating leases. The facilities in which the Company's surgical facilities or ancillary services are located are generally leased on terms whereby all costs associated with maintaining the property are paid by the Company. The lease agreements usually have lease terms ranging from 1 to 20 years, excluding renewal option periods, and have fixed payment increases or increases based on consumer price index adjustments with capped limits. Rental expense is recognized on a straight-line basis. Lease expenses for operating leases aggregated \$20,403, \$18,692 and \$14,697 for the years ended December 31, 2016, 2015 and 2014, respectively, which are primarily included in salaries, supplies and other operating expenses in the accompanying consolidated statements of operations.

Scheduled Debt and Lease Payments - Future minimum payments under non-cancelable operating leases, capital leases and debt arrangements as of December 31, 2016 are as follows:

	Operating Leases	Capital Leases	Debt
2017	\$21,554	\$2,086	\$22,076
2018	20,700	1,770	15,338
2019	20,083	1,508	14,760
2020	19,464	1,269	11,186
2021	16,931	952	9,945
Thereafter	79,368	7,120	459,873
Total payments	\$178,100	\$14,705	\$533,178
Less amount representing average imputed interest (7.2%)		(4,626)	
Present value of minimum lease payments		\$10,079	

Debt covenants -- Certain debt obligations are subject to financial covenants such as debt service and fixed charge coverage ratios. The Company is in compliance with all of its debt covenants at December 31, 2016.

Substantially all debt obligations are secured by the underlying assets of the Company. The First Lien Credit Agreement and Second Lien Notes Purchase Agreement contain certain provisions that may restrict the Company's ability to incur indebtedness, create or permit liens, declare or pay dividends and certain other restricted payments, consolidate or merge, acquire or sell assets, make certain investments, loans or other advances, enter into transactions with affiliates and change its line of business.

NOTE 10 - DEFERRED FINANCING OBLIGATIONS

During 2013, one of the Company's affiliates engaged a third-party in the construction of a replacement hospital. Due to certain provisions in the development agreement and other transaction documents, the affiliate was treated as the owner of the building during the construction phase and recorded a deferred financing obligation equal to the costs incurred related to the construction. Upon completion of the

Notes to Consolidated Financial Statements

(In thousands except years, units and per share amounts)

hospital in August 2014, it was determined that due to the Company's continuing involvement with the property, the transaction did not qualify for sale-leaseback accounting treatment under ASC 840, *Leases*. As such, the deferred financing obligation remained and all lease payments made are classified as interest expense in the accompanying consolidated statements of operations or as principal adjustments to the financing obligation. At December 31, 2016 and 2015, the balance of the obligation was \$26,047 and \$26,662, respectively, and is recorded as a deferred financing obligation on the accompanying consolidated balance sheets.

In March 2011, the Company sold all of its ownership in certain real estate associated with one of its facilities. However, due to the Company's continuing involvement with the property, the transaction did not qualify for sale-leaseback accounting treatment. The gross proceeds from the sale were recorded as a deferred financing obligation at the time of the transaction. Lease payments made subsequent to the transaction are classified as interest expense in the consolidated statements of operations or as principal adjustments to the deferred financing obligation. At December 31, 2016 and 2015, the balance of the obligation was \$13,684 and \$13,842, respectively, and is recorded as a deferred financing obligation on the accompanying consolidated balance sheets.

Future minimum lease payments, including payments classified as interest expense and principal adjustments to the deferred financing obligations, relating to the two real estate properties discussed above are as follows:

2017	\$4,592
2018	4,705
2019	4,822
2020	4,940
2021	5,062
Thereafter	29,241
Total payments	\$53,362
Less amount representing average imputed interest (10.2%)	(22,041)
Present value of minimum lease payments	\$31,321

NOTE 11 - LEASE ABANDONMENT

In August 2014, one of the Company's affiliates moved its hospital operations to a new building and abandoned its previous location. As a result, the Company recognized an abandonment loss of \$5,874 in the accompanying consolidated statement of operations for the year ended December 31, 2014. The loss consists of the net present value of future lease and property tax payments required over the five years remaining on the lease as well as a \$681 write-off of the leasehold improvements related to the abandoned location.

In October 2015, the affiliate executed an agreement with the hospital's landlord to terminate the lease through a one-time payment of \$3,572. The transaction resulted in a gain of \$509 which is recognized in gain on lease abandonment in the accompanying consolidated statement of operations for the year ended December 31, 2015.

NOTE 12 - CONTROLLING SHAREHOLDERS' EQUITY

Preferred and Common Stock - The Company has two classes of capital stock: Series A Preferred Stock and Class A Common Stock. Holders of preferred stock have no voting rights but are entitled to an 8 percent per annum dividend paid in arrears. Holders of preferred stock receive dividends prior to the payment of dividends for other classes of stock. In addition, holders of preferred stock are entitled to receive payments upon a liquidation or dissolution of the Company prior to holders of common stock in an amount equal to the original issue price of \$1,000 per share plus any unpaid dividends.

Stock Options - The Company's stock option plan provides for options to purchase up to 24,068 shares of common stock. The plan is administered by a committee of the Board of Directors that has the authority to determine the individuals to whom awards will be granted, the amount of the awards and the other terms and conditions of the awards. Each option allows the grantee to purchase one share of common stock for each option granted. All options were granted at not less than fair value at the date of the grant and vest and expire according to terms established at the grant date, vesting ratably over five years with a term not to exceed ten years.

Notes to Consolidated Financial Statements

(In thousands except years, units and per share amounts)

A summary of stock option activity and related information is as follows:

	Number of Options	Weighted-Average Exercise Price Per Share
Outstanding - December 31, 2013	19,796	\$100.00
Granted	3,750	300.35
Exercised	(2,037)	100.00
Forfeited	(4,712)	100.00
Outstanding - December 31, 2014	16,797	\$100.00
Granted	5,300	300.35
Exercised	(5,668)	100.00
Forfeited	(809)	100.00
Outstanding - December 31, 2015	15,620	\$167.98
Granted	700	699.00
Exercised	(1,155)	120.51
Forfeited	(151)	100.00
Outstanding - December 31, 2016	15,014	\$191.36
Exercisable at end of period	5,914	\$129.00

The weighted-average remaining contractual life of exercisable options outstanding as of December 31, 2016 is 5.9 years.

The fair value for stock options was estimated at the date of grant. The Company used the Black-Scholes option pricing model for option grants in the current and prior years with the following assumptions:

	2016	2015	2014
Average risk-free interest rate	1.5%	2.1%	2.7%
Expected volatility	45.0%	31.0%	31.0%
Expected forfeiture rate	12.9%	20.2%	23.8%
Expected dividend yield	0%	0%	0%
Expected life	7 years	10 years	10 years

The expected volatility is based on the historical volatility of comparable companies. The expected term of the options granted represents the average period of time that the options granted are expected to be outstanding.

Compensation expense of \$203, \$293 and \$206 related to these options was recognized for the years ended December 31, 2016, 2015 and 2014, respectively, and is included in corporate general and administrative expenses in the accompanying consolidated statements of operations. The remaining unrecognized compensation expense of \$555 will be recognized over the remaining five year vesting period as the stock options vest, using the straight line attribution method.

Notes to Consolidated Financial Statements

(In thousands except years, units and per share amounts)

NOTE 13 - INCOME TAXES

The income tax expense (benefit) for continuing operations consists of the following:

	Years ended December 31,		
	2016	2015	2014
Federal			
Current	(\$5,261)	\$9,578	\$6,110
Deferred	10,365	18,055	(1,248)
Total Federal	5,104	27,633	4,862
State			
Current	883	1,430	860
Deferred	850	452	(86)
Total State	1,733	1,882	774
Total	\$6,837	\$29,515	\$5,636

Income tax expense as a percentage of income before taxes, discontinued operations and noncontrolling interests was 13.0%, 26.5% and 17.2% for the years ended December 31, 2016, 2015 and 2014, respectively. As compared to the Federal statutory rate of 35.0%, the Company's effective tax rates reflect reductions as a result of the inclusion in the calculation of income attributable to noncontrolling interests in partnerships and limited liability companies for which income taxes are not recorded at the Company level offset somewhat by increases as a result of state income taxes and various other items.

Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of the Company's deferred tax assets and liabilities, relating to continuing operations, are as follows:

	At December 31,		
	2016	2015	
Deferred tax assets:			
Reserves and allowances	\$5,145	\$5,261	
Accrued expenses	4,193	4,515	
Net operating loss carryforwards	519	467	
Deferred tax assets	9,857	10,243	
Deferred tax liabilities:			
Gain on remeasurement of subsidiary	(26,567)	(26,655)	
Goodwill and intangible assets	(17,674)	(6,646)	
Fixed assets	(10,229)	(10,415)	
Other	(2,176)	(2,071)	
Deferred tax liabilities	(56,646)	(45,787)	
Net deferred tax liabilities	(\$46,789)	(\$35,544)	

The net deferred tax liabilities are recorded as follows:

	At December 31,		
	2016	2015	
Current deferred tax asset	\$9,857	\$10,243	
Noncurrent deferred tax liability	(56,646)	(45,787)	
Net deferred tax liabilities	(\$46,789)	(\$35,544)	

Notes to Consolidated Financial Statements

(In thousands except years, units and per share amounts)

As of December 31, 2016, Company generated approximately \$7,840 of federal net operating loss that will be carried back in its entirety to offset prior years' taxable income. For state tax purposes, the Company had a remaining net operating loss carryforward of \$6,424, \$2,492 and \$4,379 as of December 31, 2016, 2015 and 2014, respectively. The state net operating loss carryforwards will begin to expire in 2026. Management believes future profitability and the reversal of temporary tax differences will allow the Company to utilize all of its net operating losses.

The Company had income tax receivables totaling \$4,392 as of December 31, 2016, primarily related to the carryback of its 2016 federal net operating loss. The Company expects to receive the tax refunds in the next twelve months.

For income taxes related to discontinued operations, refer to Note 6.

NOTE 14 - RELATED PARTY TRANSACTIONS

The Company recognizes management fee revenue for services provided under contractual agreements with consolidated and unconsolidated affiliates as discussed in Note 2. The Company has certain receivables from unconsolidated affiliates totaling \$635 and \$812 at December 31, 2016 and 2015, respectively. These receivables are comprised of amounts due for management fees and certain operating and development expenses. Management believes the remaining amount of receivables outstanding as of December 31, 2016 is fully collectible.

The Company leases office space, operating facilities and various equipment under operating leases as discussed in Note 9. Certain of these lease commitments are with related parties. Lease expenses for operating leases with related parties aggregated \$7,880, \$8,274 and \$13,920 for the years ended December 31, 2016, 2015 and 2014, respectively, which is included in salaries, supplies and other operating expenses in the accompanying consolidated statements of operations.

The Company earns rental income by leasing available space at its facilities to physicians and other healthcare providers as discussed in Note 2. Rental income of \$3,012, \$3,598 and \$53 was recognized for the years ended December 31, 2016, 2015 and 2014, respectively, and is included in management fees and other revenue in the accompanying consolidated statements of operations.

NOTE 15 - COMMITMENTS AND CONTINGENCIES

Employment Agreements - The Company has entered into employment agreements with certain of its executive officers, which include provisions for salary and benefits continuation under certain circumstances.

General and Professional Liability - The Company, its subsidiaries and affiliated partnerships or limited liability companies are insured with respect to medical malpractice risk on a claims-made basis. The Company also maintains insurance for general liability, director and officer liability, workers' compensation claims and property. These policies are subject to deductibles.

There are known claims or incidents that may result in the assertion of additional claims, as well as claims from incidents incurred but not reported that may be asserted. Management is aware of certain claims against the Company and has adequate insurance coverage and liabilities recorded representing the Company's insurance deductible and incurred but not reported exposure for any potential claims. At December 31, 2016 and 2015, the Company has \$1,077 and \$844, respectively, in reserves related to those claims, inclusive of discontinued operations. The reserves are included in accrued expenses on the accompanying consolidated balance sheets. It is reasonably possible that recorded liabilities for self-insured claims could change in the near term. Management believes that any known claims or incidents will not have a material impact on the Company's consolidated financial position, results of operations or cash flows.

Regulatory Compliance - The healthcare industry is subject to numerous laws and regulations of federal, state and local governments. The laws and regulations governing the Medicare and Medicaid programs are extremely complex and subject to interpretation. As a result, there is at least a reasonable possibility that recorded estimates will change by a material amount in the near term. Recently, government activity has increased with respect to investigations and allegations concerning possible violations of various statutes and regulations by healthcare providers. Violations of these laws and regulations could result in imposition of significant fines and penalties, repayment for patient services previously billed and expulsion from government healthcare programs.

Based on the results of internal compliance audits conducted in 2013 and additional audits in 2015 and 2016 following a recent acquisition, a number of NSH facilities filed with CMS a self-disclosure of certain conduct that may constitute a violation of the Stark Law, 42 U.S.C. §1395nn. Filings were made pursuant to the Medicare Self-Referral Disclosure Protocol released by CMS on September 23, 2010, as revised on May 6, 2011, a process to enable healthcare providers to self-disclose actual or potential violations of the physician self-referral statute. Such filings contemplate the possibility of settlement payments, yet to be negotiated with CMS, in resolution of potential overpayment liability exposure for the conduct identified. The Company's management cannot predict with certainty the progress or final outcome of any discussions with third parties, such as government agencies. Therefore, the Company is unable to estimate the potential liability, if any, and the impact it may have on the consolidated financial statements, which could be material.

Notes to Consolidated Financial Statements

(In thousands except years, units and per share amounts)

NOTE 16 - 401k RETIREMENT PLAN

The Company adopted a defined-contribution retirement plan effective January 1, 2000, which covers all eligible employees. This plan includes a provision, at the Company's discretion, to match a portion of the employee contributions. The total 401(k) retirement plan expense was \$3,425, \$2,276 and \$1,878 for the years ended December 31, 2016, 2015 and 2014, respectively. At December 31, 2016 and 2015, accrued expenses on the accompanying consolidated balance sheets included \$3,302 and \$2,191, respectively, for the Company's matching contribution. The contribution was funded in the subsequent year.

NOTE 17 - SUBSEQUENT EVENTS

The Company evaluated events from January 1, 2017 to October 6, 2017, which is the date the consolidated financial statements were available to be issued. During this period, there were no subsequent events requiring recognition in or disclosure in notes to the consolidated financials statements other than as noted below.

On August 31, 2017, Surgery Partners, Inc., acquired NSH, excluding one consolidated subsidiary, from Irving Place Capital for approximately \$760 million. Additionally, several significant professional liability claims were concluded, the majority of which were fully covered by insurance. Approximately \$3 million was not reimbursed under the policies, although some cases are still under appeal and will be settled at a future date.

Interim Condensed Consolidated Financial Statements

INDEX

<u>DESCRIPTION</u>	<u>PAGE</u>
Condensed Consolidated Balance Sheets as of June 30, 2017 (unaudited) and December 31, 2016	2
Unaudited Condensed Consolidated Statements of Operations for the three months ended June 30, 2017 and June 30, 2016	3
Unaudited Condensed Consolidated Statements of Operations for the six months ended June 30, 2017 and June 30, 2016	4
Unaudited Condensed Consolidated Statement of Changes in Equity for the six months ended June 30, 2017	5
Unaudited Condensed Consolidated Statements of Cash Flows for the six months ended June 30, 2017 and June 30, 2016	6
Notes to Condensed Consolidated Financial Statements (unaudited)	7

Condensed Consolidated Balance Sheets

(In thousands, except share information) (Unaudited)

### 1985		June 30, 2017		December 31, 2016	
Seed of Section (1998) \$ 1,000<	Assets				
Signation (1998) (1998) (1998) 19,00	Current assets:				
1	Cash	\$ 34,748	\$	29,677	
Remain from the review of the review of the review of the review of the remain of the review of the remains of the rem		91,608		100,279	
	Supplies	14,878		14,910	
Probation of Control	Receivables from affiliates	826		635	
Control action (action of the control of th	Income tax receivable	4,392		4,392	
Total current asserts	Prepaid expenses and other current assets	7,903		10,347	
Property and equipment, net 18.25	Current assets - discontinued operations	 687		779	
Poperay and equipment team 18255 18266 Goodwill 605514 65534 Langalpha sastes, see 1943 943 Other consummous olide del affiliates 943 1826 Chapearma sees 1338 1,378 Langearma sees, discontined operations 1338 1,378 Langearma sees, discontined operations 2 1,110 1,378 Langearma sees, discontined operations 3 1,100 1,300 Langearma sees, discontined operations 3 1,100 2,300 Langearma sees, discontined operations 2 1,100 3,200 Langearma sees, discontined operations 27,137 3,200 Carcused Expurity 2 1,500 3,300 3,500 Carcused expurity 2 1,500 3,500	Total current assets	155,042		161,019	
Goodell 665.534 665.534 Inanghe saests, etc. 10.105 10.055 Investments in unconolidated affiliates 9,434 9,108 Other long-term assets 4,347 4,347 Engansaests-discontinued operations 1,378 1,378 Total assets 1,378 1,378 Total assets 8 1,134 1,378 Exhibitions 8 3,352 \$ 3,715 Accounts payable \$ 3,352 \$ 3,715 Accounts payable \$ 3,352 \$ 3,715 Accounts questions 2,713 \$ 3,600 Current maturitées deur lona and long-term étée 1,572 \$ 3,600 Current labolitées - discontinued operations 1,572 \$ 3,932 Current labolitées - discontinued operations 4,469 4,469 4,469 Congesterm labolitées - discontinued operations 3,93 3,23 3,50 3,50 3,50 3,50 3,50 3,50 3,50 3,50 3,50	Long-term assets:				
Interpation is unconsolidated affiliates 100,100 100,100 9,103 9,103 9,103 9,103 9,103 1,103<	Property and equipment, net	182,552		192,467	
Investments in monosolidated affiliates 9,435 9,108 Ober (one) como sasos 4,347 4,247 Long-term sases - discontinued operations 1,136 1,136,200 Total asces - discontinued operations 5 1,118,400 1,118,400 Lobilities and Equity 8 33,355 \$ 37,151 Accounts payable \$ 33,555 \$ 37,151 Accounts payable \$ 3,550 \$ 37,151 Accounts payable \$ 3,550 \$ 37,151 Account expenses \$ 3,550 \$ 37,151 Account popular descriptions \$ 3,500 \$ 3,500 Current maturities of capital leases and other long-term debt \$ 1,500 \$ 3,500 Current maturities of capital leases and other long-term debt, net, leas current maturities \$ 1,500 \$ 3,500 \$ 3,500 \$ 3,500 \$ 3,500 \$ 3,500 \$ 3,500 \$ 3,500 \$ 3,500 \$	Goodwill	665,534		665,534	
Other long-term assets 4,437 4,482 Long-term assets - discontinued operations 1,378 1,378 Total acts 3 1,118 5 1,316 Liabilities and Equity Use of the liabilities Corous payable \$ 3,355 \$ 3,715 Account payable \$ 3,550 3,500 3,500 Current maturities of term loan and long-term ofted 1,500 3,500 3,500 Current maturities of term loan and other long-term ofted 1,500 3,500 3,500 Current maturities of term loan and other long-term ofted 1,500 3,500 </td <td>Intangible assets, net</td> <td>100,105</td> <td></td> <td>101,625</td>	Intangible assets, net	100,105		101,625	
Long-term assers - discontinued operations 1,378 1,108,000 Total asses 5 1,111,100 1,108,000 Lightifities and Equity Use multiplities: Accound expenses 33,525 3,751 3	Investments in unconsolidated affiliates	9,443		9,163	
Paris Pari	Other long-term assets	4,347		4,842	
Carent labilities and Equity Carent labilities Carent maturities of term loan and long-term note Carent maturities of term loan and long-term note Carent maturities of capital leases and other long-term debt Carent labilities Carent	Long-term assets - discontinued operations	 1,378		1,378	
Current liabilities: S 33,525 \$ 37,151 Accuade expenses 27,137 30,019 Current maturities of tem loan and long-term note 3,650 3,650 Current maturities of capital leases and other long-term debt 17,572 19,867 Current liabilities - discontinued operations 16 3,450 Total current liabilities - discontinued operations 46,659 39,000 Current maturities of capital leases and other long-term debt, net. less current maturities 446,659 346,600 Current liabilities 446,659 38,000 39,000 Capital leases and other long-term debt, net, less current maturities 446,659 446,600 39,000 Capital leases and other long-term debt, net, less current maturities 49,409 46,000 39,000 30,000 30,000 30,000	Total assets	\$ 1,118,401	\$	1,136,028	
Current liabilities: S 33,525 \$ 37,151 Accuade expenses 27,137 30,019 Current maturities of tem loan and long-term note 3,650 3,650 Current maturities of capital leases and other long-term debt 17,572 19,867 Current liabilities - discontinued operations 16 3,450 Total current liabilities - discontinued operations 46,659 39,000 Current maturities of capital leases and other long-term debt, net. less current maturities 446,659 346,600 Current liabilities 446,659 38,000 39,000 Capital leases and other long-term debt, net, less current maturities 446,659 446,600 39,000 Capital leases and other long-term debt, net, less current maturities 49,409 46,000 39,000 30,000 30,000 30,000		_			
Accounts payable \$ 33.52 \$ 37.15 Accound expenses 27,137 32,019 Current maturities of term loan and long-term note 3.60 3.60 Current maturities of capital leases and other long-term debt 17,752 19,000 Current liabilities 20,000 9,000 Total current liabilities 446,459 446,559 Cong-term liabilities 446,559 446,550 Capital leases and other long-term debt, net, less current maturities 446,550 38,761 Capital leases and other long-term debt, net, less current maturities 34,951 46,762 Capital leases and other long-term debt, net, less current maturities 44,645 38,763 Capital leases and other long-term debt, net, less current maturities 38,961 38,763 Cheferred train-cing obligations 34,962 38,762 38,763 Deferred train-cing obligations 19,062 46,769 46,769 Cheferred train-cling interests - redemable 120,002 46,769 46,769 Chemistration of training interests - redemable 120,002 120,002 120,002 Every col	Liabilities and Equity				
Accused expenses 27,137 32,019 Current maturities of term loan and long-term note 3,650 3,650 Current maturities of capital leases and other long-term debt 17,572 19,867 Current liabilities 82,030 93,032 Total current liabilities 82,030 93,032 Long-term liabilities 446,459 446,951 Capital leases and other long-term debt, net, less current maturities 446,459 446,951 Capital leases and other long-term debt, net, less current maturities 38,967 39,361 Deferred financing obligations 39,97 30,303 Deferred tai labilities 49,498 46,789 Long-term liabilities - discontinued operations 37 33 Total current liabilities 19,000 45,781 Long-term liabilities - discontinued operations 37 33 Total labilities 120,000 45,781 Compt-term liabilities 120,000 120,000 Compt-term liabilities 120,000 120,000 Compt-term liabilities 120,000 120,000 Co	Current liabilities:				
Current maturities of term loan and long-term note 3,650 3,650 Current maturities of capital leases and other long-term debt 17,572 19,867 Current liabilities - discontinued operations 146 345 Total current liabilities 8,000 39,002 Long-term liabilities 446,459 446,561 Long-term liabilities 446,459 446,561 Erem loan and long-term note, net, less current maturities 446,459 456,661 Capital leases and other long-term debt, net, less current maturities 446,561 58,665 Operand liabilities 446,459 446,561 46,661 Deferred financing obligations 38,967 39,731 39,731 46,789 4	Accounts payable	\$ 33,525	\$	37,151	
Current maturities of capital leases and other long-term debt 17,572 19,867 Current liabilities - discontinued operations 146 345 Total current liabilities 82,030 39,303 Long-term liabilities 82,030 446,951 Term liabilities Term liabilities 446,459 446,961 Capital leases and other long-term debt, net, less current maturities 54,251 58,865 Capital leases and other long-term debt, net, less current maturities 54,251 58,865 Deferred financing obligations 38,967 39,731 Deferred tax liability 49,498 46,789 Other long-term liabilities - discontinued operations 373 338 Total liabilities 673,564 67,901 Long-term liabilities 12,992 122,081 Long-term liabilities 12,993 122,081 Long-term liabilities 12,998 46,789 Other long-term liabilities 12,998 122,081 Long-term liabilities 12,998 122,081 Companities liabilities <t< td=""><td>Accrued expenses</td><td>27,137</td><td></td><td>32,019</td></t<>	Accrued expenses	27,137		32,019	
Current liabilities - discontinued operations 146 345 Total current liabilities 80,00 93,032 Long-term liabilities 80,00 94,00 Even liabilities 446,459 446,961 Capital leases and other long-term debt, net, less current maturities 54,251 58,865 Deferred tax liability 49,498 46,799 Deferred tax liability 49,498 46,799 Deferred tax liabilities - discontinued operations 373 33 Deferred liabilities - discontinued operations 373 38,97 Long-term liabilities - discontinued operations 373 38,97 Long-term liabilities - discontinued operations 373 38,98 Long-term liabilities - discontinued operations 373 38,98 Long-term liabilities - discontinued operations 373 38,98 Deferred tax liability 49,498 46,799 48,799 Deferred tax liabilities - discontinued operations 32,999 12,200 48,799 12,200 12,200 12,200 12,200 12,200 12,200 12,200 12,200 <td>Current maturities of term loan and long-term note</td> <td>3,650</td> <td></td> <td>3,650</td>	Current maturities of term loan and long-term note	3,650		3,650	
Total current liabilities 82,030 93,032 Long-term liabilities: 346,459 446,951 Capital leases and other long-term debt, net, less current maturities 54,251 58,865 Deferred financing obligations 38,967 39,731 Deferred tax liability 49,498 46,789 Other long-term liabilities - discontinued operations 373 38 Total liabilities 673,544 687,049 Comptement sand contingencies 120,992 122,081 Committents and contingencies 120,992 122,081 Equity 57,544 57,544 57,544 Controlling shareholders' equity 1 1 1 Additional paid-in- capital 77,435 77,324 1 Retained earnings 81,229 82,637 1 Total controlling shareholders' equity 158,68 159,68 <td>Current maturities of capital leases and other long-term debt</td> <td>17,572</td> <td></td> <td>19,867</td>	Current maturities of capital leases and other long-term debt	17,572		19,867	
Long-term liabilities: 446,459 446,951 Capital leases and other long-term debt, net, less current maturities 54,251 58,865 Deferred financing obligations 38,967 39,731 Deferred tax liability 49,498 46,789 Other long-term liabilities 1,986 2,085 Long-term liabilities - discontinued operations 373 338 Total liabilities 673,564 687,801 Commitments and contingencies 673,564 687,801 Controlling interests - redeemable 120,992 122,081 Equity 1 1 Controlling shareholders' equity: 1 1 Controlling shareholders' equity: 1 1 Preferred stock, \$0,01 par value, 325,000 shares authorized, 138,482 shares issued and outstanding at June 30, 2017 and December 31, 2016 1 1 Common stock, \$0.01 par value, 325,000 shares authorized, 138,482 shares issued and outstanding at June 30, 2017 and December 31, 2016 1 1 Additional paid-in capital 77,455 77,324 Retained earnings 81,229 82,637 Total controlling shareholders	Current liabilities - discontinued operations	 146		345	
Tem loan and long-term note, net, less current maturities 446,459 446,951 Capital leases and other long-term debt, net, less current maturities 54,251 58,865 Deferred financing obligations 38,967 39,731 Deferred tax liability 49,498 46,789 Other long-term liabilities 1,986 2,085 Long-term liabilities - discontinued operations 373 38 Total liabilities 673,564 687,801 Commitments and contingencies 120,992 122,081 Equity 200,000 120,992 122,081 Controlling interests - redeemable 120,992 122,081 Equity 1 1 1 Controlling shareholders' equity: 1 1 1 Preferred sock, \$0.01 par value, 325,000 shares authorized, 117,287 shares issued and outstanding at June 30, 2017 and December 31, 2016 1 1 1 Common stock, \$0.01 par value, 325,000 shares authorized, 138,482 shares issued and outstanding at June 30, 2017 and December 31, 2016 1 1 1 Additional paid-in capital 77,455 77,324 77,324 77,324 </td <td>Total current liabilities</td> <td>82,030</td> <td></td> <td>93,032</td>	Total current liabilities	82,030		93,032	
Capital leases and other long-term debt, net, less current maturities 54,251 58,865 Deferred financing obligations 38,967 39,731 Deferred tax liability 49,498 46,789 Other long-term liabilities 1,986 2,085 Long-term liabilities - discontinued operations 373 338 Total liabilities 673,564 687,801 Commitments and contingencies Vertical substitution of the properties of the	Long-term liabilities:				
Deferred financing obligations 38,967 39,731 Deferred tax liability 49,498 46,789 Other long-term liabilities 1,996 2,085 Long-term liabilities - discontinued operations 373 338 Total liabilities 673,564 687,801 Commitments and contingencies Noncontrolling interests - redeemable 120,992 122,081 Equity 1 1 1 Controlling shareholders' equity: 1 1 1 Preferred stock, \$0.01 par value, 325,000 shares authorized, 117,287 shares issued and outstanding at June 30, 2017 and December 31, 2016 1 1 1 Common stock, \$0.01 par value, 325,000 shares authorized, 138,482 shares issued and outstanding at June 30, 2017 and December 31, 2016 1 1 1 Additional paid-in capital 77,455 77,324 82,637 Total controlling shareholders' equity 158,666 159,686 159,686 Noncontrolling interests - non-redeemable 165,159 166,183 Total equity 323,845 326,146	Term loan and long-term note, net, less current maturities	446,459		446,961	
Deferred tax liability 49,498 46,789 Other long-term liabilities 1,986 2,085 Long-term liabilities - discontinued operations 373 338 Total liabilities 673,564 687,801 Commitments and contingencies 300 120,992 122,081 Equity Controlling shareholders' equity: Preferred stock, \$0.01 par value, 325,000 shares authorized, 117,287 shares issued and outstanding at June 30, 2017 and December 31, 2016 1 1 1 1 Common stock, \$0.01 par value, 325,000 shares authorized, 138,482 shares issued and outstanding at June 30, 2017 and December 31, 2016 1 1 1 1 Additional paid-in capital 77,455 77,324 77,324 77,324 82,637 77,324 82,637 77,324 82,637 77,324 82,637 78,686 159,963 159,963 159,963 159,963 159,963 150,818 150,818 150,818 150,818 150,818 150,818 150,818 150,818 150,818 150,818 150,818 150,818 150,818 150,818 150,818 150,	Capital leases and other long-term debt, net, less current maturities	54,251		58,865	
Other long-term liabilities 1,986 2,085 Long-term liabilities - discontinued operations 373 338 Total liabilities 673,564 687,801 Commitments and contingencies Noncontrolling interests - redeemable 120,992 122,081 Equity Controlling shareholders' equity: Preferred stock, \$0.01 par value, 325,000 shares authorized, 117,287 shares issued and outstanding at June 30, 2017 and December 31, 2016 1 1 1 Common stock, \$0.01 par value, 325,000 shares authorized, 138,482 shares issued and outstanding at June 30, 2017 and December 31, 2016 1 1 1 Additional paid-in capital 77,455 77,324 77,324 77,455 77,324 Retained earnings 81,229 82,637 82,637 70 al controlling shareholders' equity 159,686 159,963 Noncontrolling interests - non-redeemable 165,159 166,183 36,146	Deferred financing obligations	38,967		39,731	
Long-term liabilities - discontinued operations 373 338 Total liabilities 673,564 687,801 Commitments and contingencies Noncontrolling interests - redeemable 120,992 122,081 Equity Controlling shareholders' equity: Preferred stock, \$0.01 par value, 325,000 shares authorized, 117,287 shares issued and outstanding at June 30, 2017 and December 31, 2016 1 1 1 Common stock, \$0.01 par value, 325,000 shares authorized, 138,482 shares issued and outstanding at June 30, 2017 and December 31, 2016 1 1 1 Additional paid-in capital 77,455 77,324 77,324 77,324 77,324 77,455 77,324 77,324 77,324 77,324 77,455 77,324 77,324 77,455 77,324 77,	Deferred tax liability	49,498		46,789	
Total liabilities 673,564 687,801 Commitments and contingencies 120,992 122,081 Noncontrolling interests - redeemable 120,992 122,081 Equity Controlling shareholders' equity: Preferred stock, \$0.01 par value, 325,000 shares authorized, 117,287 shares issued and outstanding at June 30, 2017 and December 31, 2016 1 1 Common stock, \$0.01 par value, 325,000 shares authorized, 138,482 shares issued and outstanding at June 30, 2017 and December 31, 2016 1 1 Additional paid-in capital 77,455 77,324 Retained earnings 81,229 82,637 Total controlling shareholders' equity 158,686 159,963 Noncontrolling interests - non-redeemable 165,159 166,183 Total equity 323,845 326,146	Other long-term liabilities	1,986		2,085	
Commitments and contingencies Noncontrolling interests - redeemable 120,992 122,081 Equity Controlling shareholders' equity: Preferred stock, \$0,01 par value, 325,000 shares authorized, 117,287 shares issued and outstanding at June 30, 2017 and December 31, 2016 1 1 Common stock, \$0,01 par value, 325,000 shares authorized, 138,482 shares issued and outstanding at June 30, 2017 and December 31, 2016 1 1 Additional paid-in capital 77,455 77,324 Retained earnings 81,229 82,637 Total controlling shareholders' equity 158,686 159,963 Noncontrolling interests - non-redeemable 165,159 166,183 Total equity 323,845 326,146	Long-term liabilities - discontinued operations	 373		338	
Noncontrolling interests - redeemable 120,992 122,081 Equity Controlling shareholders' equity: Preferred stock, \$0.01 par value, 325,000 shares authorized, 117,287 shares issued and outstanding at June 30, 2017 and December 31, 2016 1 1 Common stock, \$0.01 par value, 325,000 shares authorized, 138,482 shares issued and outstanding at June 30, 2017 and December 31, 2016 1 1 1 Additional paid-in capital 77,455 77,324 77,324 Retained earnings 81,229 82,637 Total controlling shareholders' equity 158,686 159,963 Noncontrolling interests - non-redeemable 165,159 166,183 Total equity 323,845 326,146	Total liabilities	 673,564		687,801	
Equity Controlling shareholders' equity: Preferred stock, \$0.01 par value, 325,000 shares authorized, 117,287 shares issued and outstanding at June 30, 2017 and December 31, 2016 1 1 Common stock, \$0.01 par value, 325,000 shares authorized, 138,482 shares issued and outstanding at June 30, 2017 and December 31, 2016 1 1 Additional paid-in capital 77,455 77,324 Retained earnings 81,229 82,637 Total controlling shareholders' equity 158,686 159,963 Noncontrolling interests - non-redeemable 165,159 166,183 Total equity 323,845 326,146	Commitments and contingencies				
Controlling shareholders' equity: 1 1 Preferred stock, \$0.01 par value, 325,000 shares authorized, 117,287 shares issued and outstanding at June 30, 2017 and December 31, 2016 1 1 Common stock, \$0.01 par value, 325,000 shares authorized, 138,482 shares issued and outstanding at June 30, 2017 and December 31, 2016 1 1 Additional paid-in capital 77,455 77,324 Retained earnings 81,229 82,637 Total controlling shareholders' equity 158,686 159,963 Noncontrolling interests - non-redeemable 165,159 166,183 Total equity 323,845 326,146	Noncontrolling interests - redeemable	120,992		122,081	
Preferred stock, \$0.01 par value, 325,000 shares authorized, 117,287 shares issued and outstanding at June 30, 2017 and December 31, 2016 1 1 Common stock, \$0.01 par value, 325,000 shares authorized, 138,482 shares issued and outstanding at June 30, 2017 and December 31, 2016 1 1 Additional paid-in capital 77,455 77,324 Retained earnings 81,229 82,637 Total controlling shareholders' equity 158,686 159,963 Noncontrolling interests - non-redeemable 165,159 166,183 Total equity 323,845 326,146	Equity				
issued and outstanding at June 30, 2017 and December 31, 2016 1 1 Common stock, \$0.01 par value, 325,000 shares authorized, 138,482 shares issued and outstanding at June 30, 2017 and December 31, 2016 1 1 Additional paid-in capital 77,455 77,324 Retained earnings 81,229 82,637 Total controlling shareholders' equity 158,686 159,963 Noncontrolling interests - non-redeemable 165,159 166,183 Total equity 323,845 326,146					
Common stock, \$0.01 par value, 325,000 shares authorized, 138,482 shares issued and outstanding at June 30, 2017 and December 31, 2016 1 1 Additional paid-in capital 77,455 77,324 Retained earnings 81,229 82,637 Total controlling shareholders' equity 158,686 159,963 Noncontrolling interests - non-redeemable 165,159 166,183 Total equity 323,845 326,146		1		1	
Retained earnings 81,229 82,637 Total controlling shareholders' equity 158,686 159,963 Noncontrolling interests - non-redeemable 165,159 166,183 Total equity 323,845 326,146	Common stock, \$0.01 par value, 325,000 shares authorized, 138,482 shares			1	
Total controlling shareholders' equity 158,686 159,963 Noncontrolling interests - non-redeemable 165,159 166,183 Total equity 323,845 326,146	Additional paid-in capital	77,455		77,324	
Noncontrolling interests - non-redeemable 165,159 166,183 Total equity 323,845 326,146	Retained earnings	 81,229		82,637	
Total equity 323,845 326,146	Total controlling shareholders' equity	 158,686		159,963	
	Noncontrolling interests - non-redeemable	 165,159		166,183	
Total liabilities and equity \$ 1,118,401 \$ 1,136,028	Total equity	323,845		326,146	
	Total liabilities and equity	\$ 1,118,401	\$	1,136,028	

Condensed Consolidated Statements of Operations

(In thousands) (Unaudited)

Three	months	ended	June	30,
-------	--------	-------	------	-----

	Till CC Illolitils C	naca same so	•
	 2017		2016
Revenues		'	
Patient service revenues (net of contractual allowances and discounts)	\$ 156,215	\$	146,786
Less: Provision for bad debts	(3,890)		(4,383)
Net patient service revenue	 152,325		142,403
Management fees and other revenue	1,423		1,493
Total revenues	153,748		143,896
Operating Expenses			
Salaries, supplies and other operating expenses	118,615		110,399
Corporate, general and administrative expenses	5,804		5,793
Depreciation and amortization	7,448		7,605
Total operating expenses	 131,867		123,797
Operating income	 21,881		20,099
Other Income (Expense)			
Interest expense, net	(9,011)		(8,918)
Other income (expense)	(4)		432
Loss on sale of assets, net	(1,343)		(192)
Equity in earnings of unconsolidated affiliates	726		560
Total other expense, net	(9,632)		(8,118)
Income before taxes, discontinued operations			
and noncontrolling interests	12,249		11,981
Income tay ayrence	(2.047)		(1 642)
Income tax expense Net income from continuing operations	 (2,047) 10,202		(1,643) 10,338
Discontinued operations:	10,202		10,330
Income from discontinued operations	50		102
Income tax expense Income from discontinued operations, net	 32		(37) 65
Net income	10,234		10,403
Less: Net income attributable to noncontrolling interests	 (10,351)		(9,041)
Net income (loss) attributable to NSH Holdco, Inc.	\$ (117)	\$	1,362

 $See\ accompanying\ notes\ to\ unaudited\ condensed\ consolidated\ financial\ statements.$

NSH HOLDCO, INC.

Condensed Consolidated Statements of Operations

Less: Net income attributable to noncontrolling interests

Net income (loss) attributable to NSH Holdco, Inc.

(In thousands) (Unaudited)

Six months ended June 30, 2017 2016 Revenues \$ 285,483 Patient service revenues (net of contractual allowances and discounts) \$ 303,443 Less: Provision for bad debts (8,782)(8,133)Net patient service revenue 295,310 276,701 Management fees and other revenue 2,947 3,133 **Total revenues** 298,257 279,834 **Operating Expenses** Salaries, supplies and other operating expenses 233,474 218,413 Corporate, general and administrative expenses 12,010 11,378 Depreciation and amortization 14,874 15,492 260,358 245,283 **Total operating expenses Operating income** 37,899 34,551 Other Income (Expense) Interest expense, net (18,005)(17,776)Other income (expense) (10)432 Loss on sale of assets, net (1,298)(109)Equity in earnings of unconsolidated affiliates 1,499 1,088 Total other expense, net (17,814)(16,365)Income before taxes, discontinued operations and noncontrolling interests 20,085 18,186 (2,493)Income tax expense (3,356)15,693 Net income from continuing operations 16,729 Discontinued operations: 96 Income from discontinued operations 252 Income tax expense (35)(92)Income from discontinued operations, net 61 160 Net income 16,790 15,853

 $See\ accompanying\ notes\ to\ unaudited\ condensed\ consolidated\ financial\ statements.$

\$

(15,028)

825

(18,198)

(1,408)

\$

NSH HOLDCO, INC.

Consolidated Statement of Changes in Equity

(In thousands, except shares)

(Unaudited)

	Preferred Stock			Comm	Common Stock			Additional Paid-In	Datainad		Noncontrolling Interests - non-		Total	
	Shares	Amou	Amount			Amount		Capital		Retained Earnings		redeemable		Total Equity
Balance: December 31, 2016	117,287	\$	1	138,482	\$	1	\$	77,324	\$	82,637	\$	166,183	\$	326,146
Noncash stock compensation	_		_	_		_		131		_		_		131
Net income	_		_	_		_		_		(1,408)		18,198		16,790
Distributions to noncontrolling														
interests	_		—	_		_		_		_		(20,073)		(20,073)
Change in noncontrolling interests from other activity, net	_		_	_		_		_		_		(238)		(238)
Change in noncontrolling interests - redeemable	_		_	_		_		_		_		1,089		1,089
Balance: June 30, 2017	117,287	\$	1	138,482	\$	1	\$	77,455	\$	81,229	\$	165,159	\$	323,845

See accompanying notes to unaudited condensed consolidated financial statements.

NSH HOLDCO, INC.

Condensed Consolidated Statements of Cash Flows

(In thousands) (Unaudited)

(In thousands) (Unaudited)	Six months ended June 30,							
		2,017		2,016				
Cash flows from operating activities								
Net income	\$	16,790	\$	15,853				
Adjustments to reconcile net income to net cash provided by operating activities:								
Provision for bad debts		8,133		8,782				
Depreciation and amortization		14,874		15,492				
Amortization of debt discount and deferred debt issuance costs		1,322		1,322				
Income from equity investments, net of distributions received		(281)		89				
Deferred income taxes		2,709		835				
Stock option and other noncash compensation expense		131		125				
Loss on sale of assets, net		1,298		109				
Net cash provided by (used in) operating activities of discontinued operations		(163)		2,377				
Change in operating assets and liabilities, net of effects of acquisitions:								
Patient accounts receivable		538		(4,520)				
Supplies		(85)		(510)				
Receivables from affiliates, prepaids and other current assets		2,570		3,432				
Other long-term assets		571		(371)				
Accounts payable and accrued expenses		(9,824)		(7,645)				
Net cash provided by operating activities		38,583		35,370				
Cash flows from investing activities								
Proceeds from (adjustment to) the sale of affiliates		2,200		(443)				
Proceeds from the sale of equity investments		_		583				
Proceeds from the sale of property and equipment		310		536				
Purchases of property and equipment		(6,870)		(6,226)				
Net cash used in investing activities		(4,360)		(5,550)				
Cash flows from financing activities			-					
Proceeds from the issuance of long-term debt		3,173		2,653				
Repayments of long-term debt		(12,106)		(9,540)				
Payments to noncontrolling interests, net		(238)		(880)				
Distributions to noncontrolling interests		(20,073)		(21,102)				
Payments for stock option repurchases, net		_		(9)				
Dividends paid		_		(20,009)				
Net cash used in financing activities		(29,244)		(48,887)				
Net increase (decrease) in cash		4,979		(19,067)				
Cash, beginning of period		30,456		39,549				
Cash, end of period	\$	35,435	\$	20,482				
Cash, end of period continuing operations	\$	34,748	\$	19,727				
Cash, end of period discontinued operations		687		755				
Non-cash transactions and supplemental cash flow information:								
Direct financing of property and equipment	\$	1,773	\$	10,329				
Interest paid		15,360		15,031				
Cash paid for income taxes, net of refunds received		660		2,723				

 $See\ accompanying\ notes\ to\ unaudited\ condensed\ consolidated\ financial\ statements.$

Notes to Condensed Consolidated Financial Statements

(*In thousands except years, units and per share amounts*)

NOTE 1 - DESCRIPTION OF BUSINESS

NSH Holdco, Inc. ("NSH Holdco, Inc.") is the sole owner of National Surgical Hospitals, Inc. and Subsidiaries, d/b/a National Surgical Healthcare ("NSH" or the "Company"), which it acquired in February 2011. NSH owns and operates surgical hospitals and ambulatory surgery centers in partnership primarily with physicians. The clinical concentration of NSH's facilities is primarily in the musculoskeletal area and includes orthopedics, spine and pain management. In addition, NSH supports general, bariatric, urology, ENT, ophthalmology and plastic surgery. Certain of the Company's surgical facilities may also provide related ancillary services, including imaging and physical therapy. As of June 30, 2017, the Company owned and operated 14 surgical hospitals and eight ambulatory surgery centers throughout the United States.

NSH Holdco, Inc. is owned by Irving Place Capital, a New York-based private equity firm, and its affiliates as well as certain members of the Company's management and board of directors. NSH commenced operations in 1998.

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of presentation - The accompanying interim condensed consolidated financial statements as of June 30, 2017 and 2016, are unaudited, and have been prepared by NSH management in accordance with accounting principles generally accepted in the United States of America for interim financial information. In the opinion of management, these financial statements include all adjustments necessary for a fair presentation of financial position, results of operations and cash flows for each period presented.

Certain information and disclosures normally included in the Company's annual audited consolidated financial statements and accompanying notes have been condensed or omitted in these accompanying interim consolidated financial statements. Accordingly the December 31, 2016 consolidated financial statements should be read in conjunction with these interim financial statements. Results for interim periods are not necessarily indicative of results for a full year. The year-end balance sheet data was derived from audited financial statements.

Management Estimates - The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect reported amounts of assets, liabilities, revenue and expenses and disclosure of contingent assets and liabilities at the date of the financial statements. These estimates and assumptions are based on management knowledge, historical trends, current events and assumptions about future events. Actual results could differ from these estimates.

Principles of Consolidation - The consolidated financial statements include all accounts of the Company and its wholly owned subsidiaries and majority-owned or controlled partnerships or limited liability companies. Ownership interests in consolidated subsidiaries held by parties other than the Company are identified and presented in the consolidated financial statements as noncontrolling interests. Consolidated net income attributable to the Company and to the noncontrolling interests are identified and presented on the face of the consolidated statements of operations; changes in ownership interests are accounted for as equity transactions. Certain transactions with noncontrolling interests are also classified within financing activities in the statement of cash flows. All significant intercompany balances and transactions have been eliminated in consolidation.

Investments in entities that the Company does not control but can exercise significant influence are accounted for using the equity method. These investments are included as investments in unconsolidated affiliates in the accompanying condensed consolidated balance sheets. The Company's share of profits and losses from these investments is reported in equity in earnings of unconsolidated affiliates in the accompanying condensed consolidated statements of operations.

The Company has several facilities that were determined to be variable interest entities ("VIEs") due to the fact that NSH has the power to direct the activities of the entities that most significantly impact their economic performance. The VIEs are required to be consolidated with NSH, the primary beneficiary, since NSH is the entity that would absorb the expected gains or losses of the VIEs that could potentially be significant. Accordingly, the equity and earnings of the VIEs held by parties other than the Company are treated as "noncontrolling interests" in the consolidated financial statements.

The Company operates in one reportable business segment, the ownership and operation of surgical hospitals and ambulatory surgical centers.

Notes to Condensed Consolidated Financial Statements

(*In thousands except years, units and per share amounts*)

Variable Interest Entities - Variable interest entities ("VIEs") are entities that, by design, either (i) lack sufficient equity to permit the entity to finance its activities independently, or (ii) have equity holders that, as a group, do not have the power to direct the activities of the entity that most significantly impact its economic performance, the obligation to absorb the entity's losses, or the right to receive the entity's residual returns. We consolidate a VIE when we are the primary beneficiary, which is the party that has both (i) the power to direct the activities that most significantly impact the VIE's economic performance and (ii) through its interests in the VIE, the obligation to absorb losses or the right to receive benefits from the VIE that could potentially be significant to the VIE.

Certain of our consolidated subsidiaries that are less than wholly owned meet the definition of VIEs. In order to determine whether we own a variable interest in a VIE, we perform qualitative analysis of the entity's design, organizational structure, primary decision makers and relevant agreements. We consolidate such VIEs if we determine that we are the primary beneficiary because (i) we have the power to direct the activities that most significantly impact the economic performance of the VIE via our rights and obligations associated with the management and operation of the VIEs' healthcare facilities, and (ii) we have the obligation, through our equity interests, to absorb losses or receive benefits that could potentially be significant to the VIE. Our loss exposure typically is limited to our equity investment in these entities.

Note that no VIE assets are subject to NSH creditors, and only one VIE liability is secured by NSH assets via a debt guarantee, which is discussed later in this footnote. Additionally, as a shareholder in the facilities, NSH is not obligated to provide financial support. The following table summarizes the carrying amount of the assets and liabilities of our material VIEs included in the Company's consolidated balance sheets (after elimination of intercompany transactions and balances):

	June 30	December 31,
	2017	2016
Assets		
Cash	\$ 22,854	\$ 22,915
Patient accounts receivable	87,183	95,853
Supplies	14,878	14,910
Property and equipment, net	134,528	142,687
Liabilities		
Accounts payable	\$ 29,070	\$ 32,001
Accrued expenses	23,017	27,217
Current maturities of capital leases and other long-term debt	13,950	19,867
Capital leases and other long-term debt, net, less current maturities	54,251	55,024
Deferred financing obligations	25,381	26,047

Revenue Recognition - The Company recognizes patient service revenue upon delivery of services to a patient. The Company receives a portion of its net patient service revenue from Medicare and Medicaid programs and commercial insurance carriers. The Company's facilities have agreements with these third-party payors that provide for payments under various fixed prices or amounts that differ from the established rates. Net patient service revenue is reported at the estimated net realizable amounts from patients, third-party payors and others as services are rendered, including estimated adjustments under reimbursement agreements with third-party payors, certain of which are subject to audit by administering agencies. These adjustments are accrued on an estimated basis and are adjusted as needed in future periods.

Allowance for Doubtful Accounts - Accounts receivable are reduced by an allowance for amounts that could become uncollectible in the future. Substantially all of the Company's receivables relate to providing healthcare services to patients at its facilities. For most payor categories, the Company reserves 100 percent of accounts aged over 150 days from the date of service. For some payor categories in certain geographic locations, additional reserves are determined using historical collection percentages rather than the aging. The Company collects substantially all of its third-party insured receivables, which include receivables from governmental agencies.

Collections are impacted by the economic ability of patients to pay and the effectiveness of the Company's collection efforts. Significant changes in payor mix, business office operations, economic conditions or trends in federal and state governmental

Notes to Condensed Consolidated Financial Statements

(*In thousands except years, units and per share amounts*)

healthcare coverage could affect the Company's collection of accounts receivable. The process of estimating the allowance for doubtful accounts requires the Company to estimate the collectability of accounts receivable, which is primarily based on its collection history, adjusted for expected recoveries and, if available, anticipated changes in collection trends. The Company also continually reviews its overall reserve adequacy by monitoring historical cash collections as a percentage of historical net patient service revenue and aged accounts receivable by payor.

Patient service revenues from continuing operations, net of contractual allowances and discounts (but before provision for bad debts), by payor source were as follows:

	Three months e	ended June 30,	Six months en	ıded June 30,		
	2017	2016	2017	2016		
Medicare	\$34,309	\$31,823	\$68,183	\$63,291		
Medicaid	3,737	4,535	7,370	8,402		
Managed care and other third-party payors	116,031	107,902	224,125	208,802		
Self-pay (including co-pays and deductibles)	2,138	2,526	3,765	4,988		
Total	\$156,215	\$146,786	\$303,443	\$285,483		

Management Fees and Other Revenue - The Company recognizes management fee revenue for services provided under contractual agreements with consolidated and unconsolidated affiliates. Amounts recognized as revenue are in accordance with contract terms. Management fees from unconsolidated affiliates totaled \$713 and \$790 for the three months ended June 30, 2017 and 2016, respectively, and \$1,533 and \$1,551 for the six months ended June 30, 2017 and 2016, respectively. The fees are included in management fees and other revenue in the accompanying condensed consolidated statements of operations. All such revenue from consolidated affiliates is eliminated in consolidation.

The Company earns rental income by leasing available space at its facilities to physicians and other healthcare providers. Rental income totaled \$710 and \$703 for the three months ended June 30, 2017 and 2016, respectively, and \$1,414 and \$1,582 for the six months ended June 30, 2017 and 2016, respectively. Rental income is included in management fees and other revenue in the accompanying condensed consolidated statements of operations.

Other Income - Under certain provisions of the American Recovery and Reinvestment Act of 2009 ("ARRA"), federal incentive payments are available to hospitals, physicians and certain other professionals ("Providers") when they adopt, implement or upgrade ("AIU") certified electronic health record ("EHR") technology or become "meaningful users," as defined under ARRA, of EHR technology in ways that demonstrate improved quality, safety and effectiveness of care. Providers can become eligible for annual Medicare incentive payments by demonstrating meaningful use of EHR technology in each period over four periods. The Company's first measurement period began July 2013. Medicaid providers can receive their initial incentive payment by satisfying AIU criteria, but must demonstrate meaningful use of EHR technology in subsequent years in order to qualify for additional payments. Hospitals may be eligible for both Medicare and Medicaid EHR incentive payments. Hospitals that are meaningful users under the Medicare EHR incentive payment program are deemed meaningful users under the Medicaid EHR incentive payment program and do not need to meet additional criteria imposed by a state. Medicaid EHR incentive payments to Providers are 100 percent federally funded and administered by the states. Before a state may offer EHR incentive payments, the state must submit and the Centers for Medicare and Medicaid Services ("CMS") must approve the state's incentive plan.

The Company recognizes Medicare EHR incentive payments in the consolidated statements of operations when: (1) the specified meaningful use criteria are met; and (2) contingencies in estimating the amount of the incentive payments to be received are resolved. The Company recognizes Medicaid EHR incentive payments for the first payment year when: (1) CMS approves a state's EHR incentive plan; and (2) a hospital acquires certified EHR technology (i.e., when AIU criteria are met). Medicaid EHR incentive payments for subsequent payment years are recognized in the period during which the specified meaningful use criteria are met.

Certain of the Company's hospitals satisfied the CMS AIU and/or meaningful use criteria during previous fiscal years and, as a result, the Company recognized Medicare and Medicaid EHR incentive payments based on available cost report information. Upon filing of the 2016 cost report in the current fiscal year, the Company modified its estimates of 2016 EHR incentive payments and recognized a reduction in the meaningful use receivable. This adjustment totaled \$6 and \$10 for the three and six months ended June 30, 2017, respectively, and is recorded as other expense in the accompanying condensed consolidated statements of operations.

Property and Equipment - Property and equipment are stated at cost. Property and equipment under capital leases are stated at the lower of the present value of the minimum lease payments or the fair value of the underlying asset. Depreciation and amortization

Notes to Condensed Consolidated Financial Statements

(*In thousands except years, units and per share amounts*)

expense is computed using the straight-line method over the estimated useful lives of the asset or, if shorter, the terms of the leases for the related assets. The estimated useful lives are 40 years for buildings, 7 to 10 years for medical and surgical equipment and 5 to 10 years for furniture and fixtures. Depreciation for software and software development is recognized over a useful life of 5 years.

Goodwill and Intangible Assets - Goodwill represents the excess value of an acquired entity over the amounts assigned to assets acquired and liabilities assumed in a business combination. Intangible assets primarily represent amounts assigned to certificates of need, tradenames, non-competition agreements, specific management contracts and other licenses.

The Company evaluates goodwill for impairment at least on an annual basis and more frequently if certain indicators are encountered. Goodwill is tested at the reporting unit level, with the fair value of the reporting unit compared to its carrying amount, including goodwill. If the fair value of a reporting unit exceeds its carrying amount, goodwill of the reporting unit is not considered to be impaired. The Company's methodology utilizes a discounted cash flow model and a market approach to estimate fair value. The fair value analysis requires significant judgments and estimates to be made by management. Changes in market conditions, among other factors, may have an impact on these estimates, which may require future adjustments to the carrying value of goodwill. Based upon the comparison of the estimated fair value to carrying value, management has made no adjustments for impairment in 2016 or 2017.

Long-Lived Assets - The carrying value of long-lived assets, including intangible assets with finite lives, is reviewed for impairment if facts and circumstances, including changes in current economic and market conditions and the operating performance of the investments, suggest that the carrying value of the asset held may not be recoverable based on the undiscounted future cash flows of the asset. In this situation, the carrying value of the asset will be reduced to its estimated fair value. No impairment of long-lived assets was identified in 2016 or 2017.

Noncontrolling Interests - redeemable - Ownership interests in consolidated subsidiaries held by parties other than the Company are identified and generally presented in the consolidated financial statements separate from the Company's equity. However, in instances in which certain redemption features that are not solely within the control of the Company are present, classification of noncontrolling interests outside of permanent equity is required. In certain circumstances, the partnership and operating agreements for the Company's surgical facilities provide that the facilities will purchase all of the physicians' ownership if certain adverse regulatory events occur, such as it becoming illegal for the physicians to own an interest in a surgical facility, refer patients to a surgical facility or receive cash distributions from a surgical facility. The noncontrolling interests for these facilities are recorded as noncontrolling interests - redeemable and reported outside of stockholders' equity in the consolidated balance sheets

	Noncontrolling Interests - redeemable
Balance: December 31, 2016	\$122,081
Net income	7,950
Distributions to noncontrolling	
interests	(8,801)
Change in noncontrolling interests	
from other activity, net	(238)
Balance: June 30, 2017	\$120,992

NOTE 3 - RECENT ACCOUNTING PRONOUNCEMENTS

Several Accounting Standards Updates ("ASUs") recently issued by the Financial Accounting Standards Board could have an impact on the Company's financial reporting. The Company has not yet evaluated the impact this new guidance may have on the condensed consolidated financial position, results of operations and cash flows. These ASUs are described below.

ASU 2017-01, "Business Combinations - Clarifying the Definition of a Business," narrows the definition of a business when evaluating whether transactions should be accounted for as asset acquisition or business combination. The ASU is effective for private companies beginning in 2019, and early adoption is permitted.

Notes to Condensed Consolidated Financial Statements

(*In thousands except years, units and per share amounts*)

ASU 2017-04, "Simplifying the Test for Goodwill Impairment," amends and revises ASC 350, *Intangibles - Goodwill and Other*, by eliminating the requirement to calculate the implied fair value of goodwill to measure a goodwill impairment charge. The ASU will be applied prospectively and is effective for private companies beginning in 2022.

NOTE 4 - DIVESTITURES

In June 2017, the Company sold the tangible net assets, exclusive of certain working capital accounts, of a critical access hospital to a third party for total consideration of \$2,200. The transaction does not qualify for presentation and disclosure as a discontinued operation under ASC 205, *Presentation of Financial Statements*. The carrying amount of the assets sold was approximately \$3,871, resulting in a net loss attributable to the Company of \$1,671. Total revenue of \$3,787 and an operating loss of \$784 are included in the accompanying consolidated statement of operations for the six months ended June 30, 2017.

The components of the net assets of the discontinued operations were as follows:

	June 30, 2017	December 31, 2016
Assets		
Cash	\$687	\$779
Total current assets	687	779
Other long-term assets	1,378	1,378
Total assets	\$2,065	\$2,157
Liabilities		
Accounts payable and accrued expenses	\$122	\$216
Income taxes payable	24	129
Total current liabilities	146	345
Deferred tax liability	373	338
Total net assets	\$1,546	\$1,474

The statements of operations for the discontinued operations were as follows:

	Three months en	nded June 30,	Six months e	nded June 30,
	2017	2016	2017	2016
Patient service revenues (net of contractual				
allowances and discounts)	\$56	\$102	\$111	\$252
Salaries, supplies and other operating expenses	6	0	15	0
Operating income	50	102	96	252
Income tax expense	(18)	(37)	(35)	(92)
Net income	\$32	\$65	\$61	\$160
Net income attributable to NSH	\$16	\$33	\$31	\$82
Net income attributable to noncontrolling interests	16	32	30	78

NOTE 5 - DEBT

Credit agreement - In June 2015, the Company entered into a First Lien Credit Agreement, which provided funding of up to \$405,000, and a Second Lien Notes Purchase Agreement, which provided funding of \$105,000.

The First Lien Credit Agreement consists of a \$365,000 Term Loan Commitment (the "First Lien Term Loan") and a \$40,000 Revolving Loan Commitment (the "Revolving Loan"). The First Lien Term Loan matures in June 2022 and had an outstanding

Notes to Condensed Consolidated Financial Statements

(*In thousands except years, units and per share amounts*)

balance of \$357,700 and \$359,524 at June 30, 2017 and December 31, 2016, respectively. The Revolving Loan is available until June 2020 and had an availability of \$40,000 at June 30, 2017 and December 31, 2016. The Company pays a 0.5% commitment fee on the average daily unused portion of the Revolving Loan. The Second Lien Notes Purchase Agreement consists of a \$105,000 Note (the "Second Lien Note"), which matures in June 2023 and had an outstanding balance of \$105,000 at June 30, 2017 and December 31, 2016. Accrued interest on the outstanding First Lien Term Loan and Second Lien Note was \$75 and \$149 at June 30, 2017 and December 31, 2016, respectively, and is included in accrued expenses on the accompanying condensed consolidated balance sheets.

Deferred Debt Issuance Costs and Original Issue Discount - At June 30, 2017 and December 31, 2016, the Company had deferred debt issuance costs, net, in the amount of \$2,478 and \$2,734, respectively, and original issue discount, net, in the amount of \$10,113 and \$11,179, respectively, both of which are netted against the carrying amount of long-term debt and capital leases on the accompanying condensed consolidated balance sheets. Amortization expense for debt issuance costs and original issue discount are included in interest expense in the accompanying condensed consolidated statements of operations.

Debt covenants -- Certain debt obligations are subject to financial covenants such as debt service and fixed charge coverage ratios. The Company is in compliance with all of its debt covenants at June 30, 2017.

Substantially all debt obligations are secured by the underlying assets of the Company. The First Lien Credit Agreement and Second Lien Notes Purchase Agreement contain certain provisions that may restrict the Company's ability to incur indebtedness, create or permit liens, declare or pay dividends and certain other restricted payments, consolidate or merge, acquire or sell assets, make certain investments, loans or other advances, enter into transactions with affiliates and change its line of business.

NOTE 6 - RELATED PARTY TRANSACTIONS

The Company recognizes management fee revenue for services provided under contractual agreements with consolidated and unconsolidated affiliates as discussed in Note 2. The Company has certain receivables from unconsolidated affiliates totaling \$826 and \$635 at June 30, 2017 and December 31, 2016, respectively. These receivables are comprised of amounts due for management fees and certain operating and development expenses. Management believes the remaining amount of receivables outstanding as of June 30, 2017 is fully collectible.

The Company leases office space, operating facilities and various equipment under operating leases, some of which are with related parties. Lease expenses for operating leases with related parties aggregated \$2,337 and \$1,942 for the three months ended June 30, 2017 and 2016, respectively, and \$4,130 and \$3,934 for the six months ended June 30, 2017 and 2016, respectively, which is included in salaries, supplies and other operating expenses in the accompanying condensed consolidated statements of operations.

The Company earns rental income by leasing available space at its facilities to physicians and other healthcare providers as discussed in Note 2. Rental income from related parties totaled \$710 and \$703 for the three months ended June 30, 2017 and 2016, respectively, and \$1,414 and \$1,582 for the six months ended June 30, 2017 and 2016, respectively. Rental income is included in management fees and other revenue in the accompanying condensed consolidated statements of operations.

NOTE 7 - COMMITMENTS AND CONTINGENCIES

Employment Agreements - The Company has entered into employment agreements with certain of its executive officers, which include provisions for salary and benefits continuation under certain circumstances.

General and Professional Liability - The Company, its subsidiaries and affiliated partnerships or limited liability companies are insured with respect to medical malpractice risk on a claims-made basis. The Company also maintains insurance for general liability, director and officer liability, workers' compensation claims and property. These policies are subject to deductibles.

There are known claims or incidents that may result in the assertion of additional claims, as well as claims from incidents incurred but not reported that may be asserted. Management is aware of certain claims against the Company and has adequate insurance coverage and liabilities recorded representing the Company's insurance deductible and incurred but not reported exposure for any potential claims. At June 30, 2017 and December 31, 2016, the Company has \$807 and \$1,077, respectively, in reserves related to those claims, inclusive of discontinued operations. The reserves are included in accrued expenses on the accompanying condensed consolidated balance sheets. It is reasonably possible that recorded liabilities for self-insured claims could change in the near term.

Notes to Condensed Consolidated Financial Statements

(*In thousands except years, units and per share amounts*)

Management believes that any known claims or incidents will not have a material impact on the Company's consolidated financial position, results of operations or cash flows.

Regulatory Compliance - The healthcare industry is subject to numerous laws and regulations of federal, state and local governments. The laws and regulations governing the Medicare and Medicaid programs are extremely complex and subject to interpretation. As a result, there is at least a reasonable possibility that recorded estimates will change by a material amount in the near term. Recently, government activity has increased with respect to investigations and allegations concerning possible violations of various statutes and regulations by healthcare providers. Violations of these laws and regulations could result in imposition of significant fines and penalties, repayment for patient services previously billed and expulsion from government healthcare programs.

Based on the results of internal compliance audits conducted in 2013 and additional audits in 2015 and 2016 following a recent acquisition, a number of NSH facilities filed with CMS a self-disclosure of certain conduct that may constitute a violation of the Stark Law, 42 U.S.C. §1395nn. Filings were made pursuant to the Medicare Self-Referral Disclosure Protocol released by CMS on September 23, 2010, as revised on May 6, 2011, a process to enable healthcare providers to self-disclose actual or potential violations of the physician self-referral statute. Such filings contemplate the possibility of settlement payments, yet to be negotiated with CMS, in resolution of potential overpayment liability exposure for the conduct identified. The Company's management cannot predict with certainty the progress or final outcome of any discussions with third parties, such as government agencies. Therefore, the Company is unable to estimate the potential liability, if any, and the impact it may have on the consolidated financial statements, which could be material.

NOTE 8 - SUBSEQUENT EVENTS

The Company evaluated events from June 30, 2017 to October 6, 2017, which is the date the consolidated financial statements were available to be issued. During this period, there were no subsequent events requiring recognition in or disclosure in notes to the consolidated financials statements other than as noted below.

On August 31, 2017, Surgery Partners, Inc., acquired NSH, excluding one consolidated subsidiary, from Irving Place Capital for approximately \$760 million. Additionally, several significant professional liability claims were concluded, the majority of which were fully covered by insurance. Approximately \$3 million was not reimbursed under the policies, although some cases are still under appeal and will be settled at a future date.

UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION

On May 9, 2017, Surgery Partners, Inc. ("Surgery Partners" or, together with its subsidiaries, the "Company"), a Delaware corporation, entered into a definitive agreement (as amended on July 7, 2017) to acquire NSH Holdco, Inc., a Delaware corporation ("NSH" or "National Surgical Healthcare"), pursuant to a merger of a wholly-owned subsidiary of the Company with and into NSH, with NSH surviving the merger (the "NSH Acquisition"). NSH is a leading owner and operator of a national network of musculoskeletal focused surgical facilities, including 7 ASCs and 15 surgical hospitals. It operates in 15 markets in partnership with approximately 1,000 affiliated physicians. NSH facilities primarily provide nonemergency surgical procedures in a number of attractive specialties, including orthopedics, neuro / spine and interventional pain management. On August 31, 2017, Surgery Center Holdings, Inc., a Delaware corporation and wholly-owned subsidiary of the Company ("SCHI"), completed its acquisition of NSH for total cash consideration of approximately \$762.9 million (the "NSH Acquisition").

Also on August 31, 2017, as part of the financing for the NSH Acquisition, Surgery Partners completed the sale and issuance of 310,000 shares of preferred stock, par value \$0.01 per share, of Surgery Partners, designated as 10.00% Series A Convertible Perpetual Participating Preferred Stock (the "Series A Preferred Stock") to BCPE Seminole Holdings LP, an affiliate of Bain Capital Private Equity, at a purchase price of \$1,000.00 per share in cash (the "Preferred Private Placement").

On June 30, 2017, as part of the financing for the NSH Acquisition, SP Finco, LLC (the "Initial Issuer"), a Delaware corporation and wholly-owned subsidiary of SCHI, completed the issuance and sale of \$370.0 million in gross proceeds of the Initial Issuer's 6.750% senior unsecured notes due 2025 (the "notes" or the "Notes"), which were deposited into an escrow account established at Wilmington Trust, National Association. The Notes mature on July 1, 2025 and bear interest at a rate of 6.750% per year, payable semi-annually on January 1 and July 1 of each year, beginning on January 1, 2018. On August 31, 2017, in connection with the closing of the NSH Acquisition, the gross proceeds of the Notes were released from the escrow account to SCHI, and the Initial Issuer merged with and into SCHI, with SCHI surviving such merger (the "Initial Issuer Merger") and assuming, by operation of law, the rights and obligations of the Initial Issuer under the notes and the indenture governing such notes.

Also on August 31, 2017, as part of the financing for the NSH Acquisition, SP Holdco I, Inc., a Delaware corporation and wholly-owned subsidiary of the Company, SCHI and certain wholly-owned subsidiaries of SCHI entered into a credit agreement with Jefferies Finance LLC, as administrative agent and collateral agent, and the other financial institutions party thereto from time to time, providing for a \$1,290.0 million senior secured term loan and a \$75.0 million revolving credit facility (collectively, the "Senior Secured Credit Facilities").

On May 9, 2017, the Company and H.I.G. Surgery Centers, LLC, in its capacity as the stockholders representative, entered into an agreement to amend that certain Income Tax Receivable Agreement, dated September 30, 2015 (as amended, the "TRA"), pursuant to which the Company agreed to make payments to H.I.G. in its capacity as the stockholders representative pursuant to a fixed payment schedule. The amendment to the TRA became effective on August 31, 2017.

The NSH Acquisition, the Preferred Private Placement, the issuance of the Notes, the escrow of the gross proceeds of the Notes and eventual release of such gross proceeds from escrow, the entry into and borrowings under the Senior Secured Credit Facilities, the Initial Issuer Merger, the repayment the Existing NSH Debt (as defined herein), the repayment of the Company's Existing Credit Facilities (as defined herein), the payments pursuant to the TRA, and the payment of the fees and expenses related to the foregoing are collectively referred to as the "Transactions."

The unaudited pro forma condensed combined statement of operations of Surgery Partners for the year ended December 31, 2016 gives effect to the Transactions as if they had occurred on January 1, 2016. The unaudited pro forma condensed combined statement of operations of Surgery Partners for the six months ended June 30, 2017 gives effect to the Transactions as if they had occurred on January 1, 2016. The unaudited pro forma condensed combined balance sheet of Surgery Partners as of June 30, 2017 gives effect to the Transactions as if they occurred on June 30, 2017 and combines the unaudited condensed consolidated historical balance sheets of each of the Company and NSH as of June 30, 2017.

The following unaudited pro forma condensed combined financial information has been derived from and should be read in conjunction with:

- the historical consolidated financial statements and related notes of Surgery Partners, as of and for the year ended December 31, 2016, included in Surgery Partners' Annual Report on Form 10-K, filed with the SEC on March 10, 2017;
- the historical consolidated financial statements and related notes of NSH as of and for the year ended December 31, 2016, included in NSH's 2016 Annual Financial Statements and filed as Exhibit 99.1 to Surgery Partners' Current Report on Form 8-K to which this Exhibit 99.3 is filed;
- the historical condensed consolidated financial statements and related notes of Surgery Partners as of and for the six months ended June 30, 2017, included in Surgery Partners' Quarterly Report on Form 10-Q, filed with the SEC on August 9, 2017; and
- the historical condensed consolidated financial statements and related notes of NSH as of and for the six months ended June 30, 2017, included in NSH's Q2 2017 Quarterly Review Report for the six months ended June 30, 2017 and filed as Exhibit 99.2 to Surgery Partners' Current Report on Form 8-K to which this Exhibit 99.3 is filed.

The consolidated financial statements and accounting records of NSH used to derive the unaudited pro forma combined condensed consolidated financial information are based on the historical consolidated results of operations and historical cost basis of the assets and liabilities of NSH, as adjusted to account for the exclusion of Casper Medical Center, LLC, a Wyoming limited liability company and NSH Wyoming Inc., a Wyoming corporation (together with Casper Medical Center, LLC, "Casper"), which were not acquired by the Company as part of the NSH Acquisition. As a result of applicable Securities and Exchange Comission and public company financial reporting requirements, the historical consolidated results of operations and financial position of NSH filed with this Current Report on Form 8-K include the impact of Casper in all respects. Thus, the unaudited pro forma combined condensed consolidated financial information does not reflect the presentation and classification of NSH's operations in the same manner as NSH's historical consolidated financial statements.

The unaudited pro forma condensed combined financial statements have been prepared by our management for illustrative purposes only and are not necessarily indicative of the consolidated financial position or results of operations that would have been realized had the Transactions occurred on the dates indicated, nor is it meant to be indicative of any future consolidated financial position or future results of operations that the combined company will experience. The pro forma adjustments are based on the preliminary assumptions and information available that management believes are reasonable under the circumstances and give pro forma effect to events that are (1) directly attributable to the Transactions on a pro forma basis, (2) factually supportable and (3) with respect to the unaudited pro forma condensed combined statements of operations, expected to have a continuing impact on the combined results. The unaudited pro forma condensed combined statements of operations exclude certain non-recurring charges that may have been or were incurred in connection with the Transactions, including certain expenses related to the Transactions, including acquisition related investment banker and professional fees of both Surgery Partners and NSH and the write-off of bridge commitment fees that were incurred in connection with the closing of the Transactions. At the closing of the Transactions, we recorded an expense to reflect these charges, which, in the aggregate, was \$48.6 million. Such amounts have been reflected in the unaudited pro forma condensed combined balance sheet.

The unaudited pro forma financial information should be read in conjunction with the historical audited consolidated financial statements and the accompanying notes and the audited and unaudited condensed consolidated financial statements and the accompanying notes of each of Surgery Partners and NSH. The unaudited pro forma condensed combined financial statements do not purport to represent what our results of operations, balance sheet data or financial information would have been if the Transactions had occurred as of the dates indicated or what such results will be for any future periods.

The accounting for the NSH Acquisition is dependent upon a valuation that is preliminary and is subject to change. Management will finalize these amounts as it obtains the information necessary to complete the measurement processes. Fair value measurement can be highly subjective and the reasonable application of measurement principles may result in a range of alternative estimates using the same facts and circumstances. Accordingly, the pro forma adjustments are preliminary and have been made solely for the purpose of these unaudited pro forma condensed combined financial statements. Differences between these preliminary estimates and the final acquisition accounting may occur. The differences, if any, may have a material impact on Surgery Partners' future results of operations and financial position. The final valuations are expected to be completed as soon as practicable, but no later than one year after the consummation of the NSH Acquisition.

SURGERY PARTNERS, INC. Unaudited Pro Forma Condensed Combined Balance Sheet As of June 30, 2017

(in thousands, except shares and per share amounts)		Historical Surgery Partners		Historical National Surgical Healthcare Adjusted ^(A)		Surgery Partners Acquisition Adjustments ^(T)	NSH Acquisition Adjustments ^(B)	Financing Adjustments		Pro-Forma Combined
ASSETS				,			,			
Current assets:	\$	57,034	¢	31,229	¢		\$(742,920) ^(D)	\$591,730(F)	¢	198,461
Cash and cash equivalents	Ф	57,034	Ф	31,229	Ф	_	\$(742,920)(5)		Þ	190,401
								310,000(E)		
							(9,750) ^(O)	(38,863) ^(O)		
Accounts receivable, less allowance for doubtful accounts		215,294		85,778		(34,022)	(9,247) ^(S)	_		257,803
Inventories		29,680		13,845		(356)	1,141 ^(S)	_		44,310
Prepaid expenses and other current assets		42,332		11,437		(6,091)	(687)	(6,591) ^(R)		37,113
							(3,287) ^(T)			
Acquisition escrow asset		7,971				(3,401)		_		4,570
Total current assets	\$	352,311	\$	142,289	\$	(43,871) \$	(764,750) \$	856,277	\$	542,257
Property and equipment, net		205,744		172,185		5,968	2,189 ^(S)	_		386,086
Intangible assets, net		43,421		94,249		(14,450)	(66,509)(S)	_		56,711
Goodwill		1,569,408		588,211		834,184	256,545	_		3,248,348
Investments in and advances to affiliates		34,488		9,443		18	20,294 ^(T)	_		64,243
Restricted invested assets		315		_				_		315
Financing escrow asset		370,000		_		_	19,600 ^(U)	(370,000) ^(Q)		19,600
Long-term deferred tax asset		80,166		_		100,587	27,775 ^(S)	(4,266) ^(P)		204,263
Other long-term assets		15,634		5,716		(1,515)	(1,378)	4,967 ^(F)		23,424
							27,775 ^(T)			
Total assets	\$	2,671,487	\$	1,012,093	\$	880,921 \$	(506,233) \$	486,979	\$	4,545,247
LIABILITIES AND STOCKHOLDERS' EQUITY										
Current liabilities:										
Accounts payable	\$	48,210	¢	26,220	¢	(12,941)	\$3,432 ^(S) \$	_	¢	64,921
Accrued payroll and benefits	Ф	27,437	Ф	25,051	Ф	(1,755)	2,262 ^(S)		.p	52,996
Acquisition escrow liability		7,971		23,031		(3,401)				4,570
Other current liabilities		72,465		146		(7,503)	(146)	(3,663)(F)		79,507
outer current monnico		72,100		110		(7,500)	· ´	(3,003)(7		75,507
Comment and training of land towns dalate		20.010		10.770		2.007	18,208(S)	2 400(F)		F2 10C
Current maturities of long-term debt		29,919		19,779		3,607	(3,509) ^(D)	2,400 ^(F)		52,196
Total current liabilities		186,002		71,196		(21,993)	20,248	(1,263)		254,190
Long-term debt, less current maturities		1,795,265 122,351		491,144			(448,374)(D)	239,741(F)		2,077,776 78,498
Long-term tax receivable agreement liability Acquisition escrow long-term liability		122,331		_		(43,853)	19,600(U)	_		19,600
Other long-term liabilities		76,101		85,760		13,021	(373)	_		129,000
Other folig-term habilities		70,101		03,700		13,021	, ,			129,097
							(45,412) ^(S)			
Noncontrolling interests, redeemable		176,252		96,057		(58,571)	(107,896) ^(S)			105,842
Series A Convertible Preferred Stock		_		_		_	_	310,000 ^(E)		310,000
Stockholders' equity:										
Common stock		488		_		_	_	_		488
Additional paid-in-capital		324,340		77,457		395,777	(77,457)			720,117
Retained deficit		(318,576)		25,320		393,969	(29,464)	(18,370)(F)		_
							(9,750) ^(O)	(38,863) ^(O)		
								(4,266) ^(P)		
Total Surgery Partners stockholders' equity	_	6,252		102,777		789,746	(116,671)	(61,499)		720,605
Noncontrolling interests, nonredeemable		309,264		165,159		202,571	172,645 ^(S)	(01,439)		849,639
Total equity		315,516		267,936		992,317	55,974	(61,499)		1,570,244
	\$	2,671,487	•	1,012,093	¢	880,921 \$	(506,233) \$	486,979	¢	4,545,247
Total liabilities and stockholders' equity	Φ	2,0/1,40/	Φ	1,012,093	Φ	000,921 \$	(300,233) \$	400,979	Ψ	4,343,447

 $See\ the\ accompanying\ notes\ to\ Unaudited\ Pro\ Forma\ Condensed\ Combined\ Financial\ Information.$

SURGERY PARTNERS, INC. Unaudited Pro Forma Condensed Combined Statements of Operations Year Ended December 31, 2016

(in thousands, except shares and per share amounts)	Historical Surgery Partners	Historical National Surgical Healthcare Adjusted ^(G)	Surgery Partners Acquisition Adjustments	NSH Acquisition Adjustments	Financing Adjustments	Pro-Forma Combined
Revenues:						
Net patient services revenues	\$ 1,137,110	\$ 527,494	\$	\$ - \$	— \$	1,664,604
Other services revenues	2,967	6,266		480 ^(J)		9,713
Management fee income	5,362	0,200	<u> </u>		_	5,362
Total revenues	1,145,438	533,760	_	480	_	1,679,678
Operating expenses:						
Salaries and benefits	357,175	153,309	_	_	_	510,484
Supplies	269,239	138,535	_	_	_	407,774
Professional and medical fees	81,185	14,660	_	_	_	95,845
Rent and lease expense	52,147	19,857	_	_	_	72,004
Other operating expenses	61,450	66,146	_	_	_	127,596
Total cost of revenues	821,196	392,507	_	_	_	1,213,703
General and administrative expense	60,246	20,145	_	(602) ^(C)	_	79,586
General and duministrative expense	00,240	20,140				73,300
D 12 1 2 2	20.551	27.000	(15.120)(7)	(203) ^(N)		20.001
Depreciation and amortization	39,551	27,086	(15,138) ^(V)	(11,538) ^(H)	_	39,961
Provision for doubtful accounts	24,212	13,967	_	_	_	38,179
Income on equity investments	(4,764)	(2,796)	_	_	_	(7,560)
Loss on disposal of investments and long-lived assets, net	2,355	591	_	_	_	2,946
Merger Transaction Costs	8,738	_	_	(700) ^(C)	_	8,038
Loss on debt extinguishment	11,876	_	_	_	_	11,876
Gain on litigation	(14,101)	_	_	_	_	(14,101)
Electronic health record incentives	(408)	(2,919)	_	_	_	(3,327)
Other Expense	55	(=,===)	_	_	_	55
Total operating expenses	948,956	448,581	(15,138)	(13,043)		1,369,356
Operating income	196,482	85,179	15,138	13,523		310,323
Tax receivable agreement expense	(3,733)	03,175	13,130	13,323	_	(3,733)
Interest expense, net	(100,571)	(34,947)	1,232 ^(W)		30,155 ^(I)	(152,569)
interest expense, net	(100,571)	(34,347)	1,232		•	(132,303)
	_				(42,839) ^(K)	
					(5,600) ^(P)	
Income (loss) before income taxes	92,178	50,232	16,370	13,523	(18,284)	154,020
Provision for income taxes	7,095	6,837	6,221 ^(L)	5,139 ^(L)	(6,948) ^(L)	18,344
Income (loss) from continuing operations	85,083	43,395	10,150	8,384	(11,336)	135,677
Less: Net income attributable to noncontrolling interests	(75,630)	(36,494)	_	_	_	(112,124)
Net income (loss) attributable to Surgery Partners	9,453	6,901	10,150	8,384	(11,336)	23,553
Less: Preferred Dividends	_	_	_	_	(63,531) ^(E)	(63,531)
Net income (loss) income attributable to Common						
Shareholders	\$ 9,453	\$ 6,901	\$ 10,150	\$ 8,384 \$	(74,867) \$	(39,979)
Net income (loss) per share attributable to common stockholders:						
Basic	\$ 0.20				\$	(0.83)
Diluted ⁽¹⁾	\$ 0.20				\$	(0.83)
Weighted average common shares outstanding:						
Basic	48,018,944					48,018,944
Diluted ⁽¹⁾	48,190,738					48,018,944
Difficer.	40,190,/38					40,010,944

⁽¹⁾ The impact of potentially dilutive securities for the pro forma combined financials was not considered because the effect would be anti-dilutive for the period.

 $See \ the \ accompanying \ notes \ to \ Unaudited \ Pro \ Forma \ Condensed \ Combined \ Financial \ Information.$

SURGERY PARTNERS, INC. Unaudited Pro Forma Condensed Combined Statements of Operations Six Months Ended June 30, 2017

Register services revenues	(in thousands, except shares and per share amounts)	Historical Surg Partners	gery	Historic National Surgical Healthcare Adjusted ^(M)	Surgery Partners Acquisition Adjustments	NSH Acquisition Adjustments	Financin Adjustmer		Pro Forma Combined
Per services revenues	Revenues:								
Annagement for Income 2,50	Net patient services revenues	\$ 565	5,343 \$	\$ 278,267	\$ —	\$ —	\$	— \$	\$ 843,610
State Stat	Other services revenues	(5,663	2,916	_	240 ^(J)		_	9,819
Separating cymestric Separating cymestric	Management fee income		2,530	_	_	_		_	2,530
Second place 1999	Total revenues	574	4,536	281,183	_	240		_	855,959
upplies 145,244 35,859 — — — — 181,103 74,141	Operating expenses:								
Mary	Salaries and benefits	179	9,909	40,115	_	_		_	220,024
Second and lease expense 17,300 5,179	Supplies	145	5,244	35,859	_	_		_	181,103
Section Sect	Professional and medical fees	43	3,702	3,439	_	_		_	47,141
	Rent and lease expense	27	7,300	5,179	_	_		_	32,479
Sees	Other operating expenses	32	2,245	122,974	_	_		_	155,219
Page	Total cost of revenues	428	3,400	207,567	_	_		_	635,967
Page	General and administrative expense	34	4,196	12,010	_	(699) ^(P)		_	45,375
Page						(132) ^(N)			
Transition for doubtful accounts 11,463 8,399 — — — — — 19,802 accome on equity investments 2,252	Depreciation and amortization	22	2.525	13.093	(10,318) ^(V)	` ′		_	19.981
Come on equity investments Come on equity investment Come on equity	Provision for doubtful accounts							_	
1,601	Income on equity investments				_	_		_	(3,751)
Reger Transaction Costs 3,241	Loss on disposal of investments and long-lived assets, net		-		_	_		_	
Control Cont	Merger Transaction Costs	3	3,241	_	_	(3,241) ^(C)		_	_
other Income (2) — — — — — — — — — — — — — — — — — — —	Gain on litigation settlements	(3	3,794)	_	_	_		_	(3,794)
Second S	Electronic health record incentives		(302)	10	_	_		_	(292)
Page	Other Income		(2)	_	_	_		_	(2)
14,894 14,894 16,101 1	Total operating expenses	495	5,076	240,867	(10,318)	(9,391)		_	716,223
Common Closs Defore income taxes 28,678 22,584 10,935 9,391 (8,203 63,624 10,935	Operating income	79	9,460	40,316	10,318	9,391			139,726
Common C	Interest expense, net	(50),782)	(17,732)	616 ^(W)	_	14,89) 4 ^(I)	(76,101)
1,029 3,496 4,1556 3,6606 (3,117)6 3,747 1,0000 (1,0000 1									
19,088 6,779 5,971 (5,086) 55,382	Income (loss) before income taxes	28	3,678	22,584	10,935	9,391	(8,2	203)	63,624
Companies Comp	Provision for income taxes	2	2,629	3,496	4,155 ^(L)	3,660 ^(L)	(3,117	7) ^(L)	8,747
Company Comp	Income (loss) from continuing operations	26	6,049	19,088	6,779	5,971	(5,0	086)	55,382
Agrithers (7,225) 425 6,779 5,971 (5,086) 3,445 (14,740)	Less: Net income attributable to noncontrolling interests	(33	3,274)	(18,663)	_	_		_	(51,937)
Sect (loss) income attributable to Common \$ (7,225) \$ 425 \$ 6,779 \$ 5,971 \$ (19,826) \$ (11,295) \$	Net (loss) income attributable to Surgery Partners	(7	7,225)	425	6,779	5,971	• • •		3,445
State Stat	Less: Preferred Dividends			_		_	(14,740)) ^(E)	(14,740)
tockholders: Basic \$ (0.15) \$ (0.22) Diluted(1) \$ (0.15) \$ (0.22) Veighted average common shares outstanding: Basic 48,112,909	Net (loss) income attributable to Common Shareholders	\$ (7	7,225) \$	\$ 425	\$ 6,779	\$ 5,971	\$ (19,8	826) \$	(11,295)
Diluted(1) \$ (0.15) \$ (0.22) Veighted average common shares outstanding: 8 48,112,909 Basic 48,112,909 48,112,909	Net loss per share attributable to common stockholders:								
Veighted average common shares outstanding: Basic 48,112,909 48,112,909	Basic	\$	(0.15)					\$	\$ (0.22)
Basic 48,112,909 48,112,909	Diluted ⁽¹⁾	\$	(0.15)					\$	\$ (0.22)
	Weighted average common shares outstanding:								
Diluted ⁽¹⁾ 48,112,909 48,112,909	Basic	48,112	2,909						48,112,909
	Diluted ⁽¹⁾	48,112	2,909						48,112,909

⁽¹⁾The impact of potentially dilutive securities for the period was not considered because the effect would be anti-dilutive for the period.

 $See \ the \ accompanying \ notes \ to \ Unaudited \ Pro \ Forma \ Condensed \ Combined \ Financial \ Information.$

Notes to Unaudited Pro Forma Condensed Combined Financial Information of Surgery Partners, Inc.

(A) For presentation purposes, the historical results of Casper, which were not acquired by the Company as part of the NSH Acquisition, have been adjusted out of the NSH financial information presented below.

NATIONAL SURGICAL HEALTHCARE Unaudited Adjusted Condensed Balance Sheet As of June 30, 2017

(in thousands)		Historical National Surgical Healthcare (Unaudited)		Historical Casper	Historical National Surgical Healthcare Adjusted
ASSETS					
Current assets:	ď	24.740	ф	2.510	Ф 24.220
Cash and cash equivalents	\$	34,748	3	3,519	
Accounts receivable, less allowance for doubtful accounts		91,608		5,830	85,778
Inventories		14,878		1,033	13,845
Prepaid expenses and other current assets		13,808		2,371	11,437
Total current assets		155,042		12,753	142,289
Property and equipment, net		182,552		10,367	172,185
Intangible assets, net		100,105		5,856	94,249
Goodwill		665,534		77,323	588,211
Investments in and advances to affiliates		9,443		_	9,443
Other long-term assets		5,725		9	5,716
Total assets	\$	1,118,401	\$	106,308	\$ 1,012,093
LIABILITIES AND STOCKHOLDERS' EQUITY					
Current liabilities:					
Accounts payable	\$	33,525	\$	7,305	\$ 26,220
Accrued payroll and benefits		27,137		2,086	25,051
Other current liabilities		146		_	146
Current maturities of long-term debt		21,222		1,443	19,779
Total current liabilities		82,030		10,834	71,196
Long-term debt, less current maturities		500,710		9,566	491,144
Other long-term liabilities		90,824		5,064	85,760
Long-term liabilities of discontinued operations		_		_	_
Noncontrolling interests, redeemable		120,992		24,935	96,057
Stockholders' equity:					
Additional paid-in-capital		77,457		_	77,457
Retained deficit	_	81,229		55,909	25,320
Total stockholders' equity	'	158,686		55,909	102,777
Noncontrolling interests, nonredeemable		165,159		_	165,159
Total equity		323,845		55,909	267,936
Total liabilities and stockholders' equity	\$	1,118,401	\$	106,308	\$ 1,012,093

(B) The NSH Acquisition has been accounted for as a business combination in accordance with ASC 805, Business Combinations. The pro forma adjustments reflect the NSH Acquisition under the acquisition method of accounting as set forth below. In calculating the pro forma adjustments, the fair value of NSH's identifiable assets acquired and liabilities assumed have been recorded on a preliminary basis. Therefore, the purchase price allocation is subject to adjustments and such adjustments may be material.

PURCHASE PRICE ALLOCATION SUMMARY ON NSH ACQUISITION

(in thousands)
Purchase Price:

Total fair value of net assets acquired:

Fair Value of Noncontrolling interest:

Cash consideration:	\$ 762,850
NSH pre-acquisition debt paid:	59,186
Allocation of purchase price:	
Cash and cash equivalents	51,159
Accounts receivable, less allowance for doubtful accounts	76,531

Accounts receivable, less allowance for doubtful accounts	/6,531
Inventories	14,986
Prepaid expenses and other current assets	18,007
Property and equipment, net ⁽¹⁾	174,374
Intangible assets, net ⁽³⁾	27,741
Investments in advances to affiliates	29,737
Other long-term assets	33,491
Accounts payable	(29,652)
Accrued payroll and benefits	(27,313)
Other current liabilities	(18,355)
Other long-term liabilities	(47,461)
Other long-term assets Accounts payable Accrued payroll and benefits Other current liabilities	33,491 (29,652) (27,313) (18,355)

Goodwill⁽²⁾ \$ 844,756

303,245 325,965

⁽²⁾ Represents the preliminary excess of purchase price over the fair values of assets acquired and liabilities assumed as a result of the NSH Acquisition. Approximately \$153.5 million of the total goodwill is expected to be deductible for income tax purposes (dollars in thousands):

Amount Goodwill recorded in NSH Acquisition	\$844,756
Eliminate NSH's existing goodwill	\$588,211
Net adjustment	\$256,545

⁽³⁾ The following table is a summary of the adjustment to record the fair value of acquired intangible assets (dollars in thousands):

Certificates of need	\$711
Tradenames	0
Non-compete agreements	0
Management contracts	26,900
Licenses	130
Eliminate NSH's existing intangible assets	(94,249)
Net adjustment	\$(66,509)

(C) Represents the adjustments to eliminate non-recurring amounts directly attributable to the NSH Acquisition, including transaction fees and expenses, recorded in the historical financial statements.

⁽¹⁾ Represents adjustments to reflect the differences in depreciation and amortization expense historically recorded and what would have been recorded during the same periods.

- (D) Represents adjustments to reflect the repayment of historical indebtedness, and related unamortized deferred financing fees that will be repaid at the closing of the NSH Acquisition, including the Existing NSH Debt.
- (E) Represents adjustments to account for the issuance of the Series A Preferred Stock and the related accumulated preferred dividend.
- (F) Represents the adjustments to account for the refinancing of the Existing Credit Facilities, issuance of the Notes and the related loan costs and interest payable balances. The related cash impact of this refinancing transaction is as follows:

Net additional first lien borrowing	\$ 362,750
Senior unsecured notes due 2025 borrowing	370,000
Revolver pay-down	(91,000)
Subordinated notes pay-off	(1,000)
Accrued interest payment	(3,663)
Receipt of funds in escrow	9,491
Payment of new loan costs	(54,848)
Net cash effect	\$ 591,730

(G) For presentation purposes, the historical results of Casper, which will not be acquired by the Company as part of the NSH Acquisition, have been adjusted out of NSH financial information below.

NATIONAL SURGICAL HEALTHCARE Unaudited Adjusted Condensed Statement of Income Year ended December 31, 2016

(in thousands)	Historical National Surgical Healthcare Audit	Historical Casper	Historical National Surgical Healthcare Adjusted
Revenues:			
Net patient services revenues	\$ 589,946 \$	62,452 \$	527,494
Other services revenues	6,307	41	6,266
Total revenues	596,253	62,493	533,760
Operating expenses:			
Salaries and benefits	178,551	25,242	153,309
Supplies	151,529	12,993	138,535
Professional and medical fees	19,164	4,504	14,660
Rent and lease expense	24,021	4,164	19,857
Other operating expenses	75,775	9,629	66,146
Total cost of revenues	449,040	56,533	392,507
General and administrative expense	20,145	_	20,145
Depreciation and amortization	30,828	3,742	27,086
Provision for doubtful accounts	13,561	(406)	13,967
Income on equity investments	(2,796)	_	(2,796)
Loss (gain) on disposal of investments and long-lived assets, net	587	(4)	591
Electronic health record incentives	 (3,156)	(237)	(2,919)
Total operating expenses	508,209	59,628	448,581
Operating income	88,044	2,865	85,179
Interest expense, net	(35,575)	(628)	(34,947)
Income before income taxes	52,469	2,237	50,232
Provision for income taxes	(6,837)	_	(6,837)
Income from continuing operations	45,632	2,237	43,395
Less: Net income attributable to noncontrolling interests	(36,782)	(288)	(36,494)
Net income attributable to National Surgical Healthcare	\$ 8,850 \$	1,949 \$	6,901

(H) Represents the following adjustments to depreciation and amortization expense for the acquisition of NSH.

(dollars in thousands)	Fiscal Year Ended December 31, 2016	Six Months Ended June 30, 2017
Pro forma depreciation and amortization ⁽¹⁾	\$ 15,548	\$ 7,774
Less: Depreciation and amortization, adjusted	(27,086)	(13,093)
Pro forma adjustment	\$ (11,538)	\$ (5,319)

⁽¹⁾ Represents adjustments to reflect the differences in depreciation and amortization expense historically recorded and what would have been recorded during the same periods.

⁽I) Represents adjustments to eliminate interest expense on historical indebtedness that will be repaid at the closing of the Transactions, including the Existing NSH Debt.

⁽J) Represents the management fees to be received by Surgery Partners and NSH under the pre-existing management fee agreement with Casper.

- (K) Represents adjustments to account for the repayment of the Existing Credit Facilities, issuance of the new Notes and the related loan costs and interest payable balances.
- (L) Represents adjustments to record the income tax effects of the Pro Forma Statements of Earnings adjustments using a combined statutory and federal rate of 38%.
- (M) For presentation purposes, the historical results of Casper, which will not be acquired by the Company as part of the NSH Acquisition, have been adjusted out of NSH financial information presented below.

NATIONAL SURGICAL HEALTHCARE Unaudited Adjusted Condensed Statement of Income Six Months ended June 30, 2017

		Historical National Surgical		Historical National Surgical
(in thousands)		Iealthcare Jnaudited)	Historical Casper	Healthcare Adjusted
Revenues:	· ·	·	•	
Net patient services revenues	\$	303,443 \$	25,176 \$	278,267
Other services revenues		2,947	31	2,916
Total revenues		306,390	25,207	281,183
Operating expenses:				
Salaries and benefits		46,348	6,232	40,115
Supplies		38,496	2,637	35,859
Professional and medical fees		4,119	680	3,439
Rent and lease expense		6,188	1,009	5,179
Other operating expenses		138,323	15,349	122,974
Total cost of revenues		233,474	25,907	207,567
General and administrative expense		12,010	_	12,010
Depreciation and amortization		14,874	1,781	13,093
Provision for doubtful accounts		8,133	(206)	8,339
Income on equity investments		(1,499)	_	(1,499)
Loss (gain) on disposal of investments and long-lived assets, net		1,298	(49)	1,347
Electronic health record incentives		10	_	10
Total operating expenses		268,300	27,433	240,867
Operating income		38,090	(2,226)	40,316
Interest expense, net		(18,005)	(273)	(17,732)
Income before income taxes and discontinued operations		20,085	(2,499)	22,584
Provision for income taxes		(3,356)	140	(3,496)
Income from continuing operations		16,729	(2,359)	19,088
Less: Net income attributable to noncontrolling interests		(18,198)	465	(18,663)
Net income (loss) attributable to National Surgical Healthcare	\$	(1,469) \$	(1,894) \$	425

- (N) Represents the elimination of stock compensation expense related to NSH's stock option plan that will be terminated at the closing of the NSH Acquisition.
- (O) Represents adjustments for historic stock compensation expense that should be eliminated in the pro forma condensed combined statements of operations.
- (P) Represents the adjustments to revalue the liability in connection with the TRA and the related deferred tax asset change and interest expense adjustment.
- (Q) As stipulated within the Escrow Agreement, unless the consummation of the offering of the Notes occurred simultaneously with the consummation of the NSH Acquisition, the Initial Issuer was required to deposit within a segregated

escrow account (for the benefit of the holders of the notes), 100% of the gross proceeds of the offering plus an additional amount sufficient to fund a special mandatory redemption of the notes on October 5, 2017. This adjustment represents the elimination of the gross receivable associated with the escrow account which is eliminated upon the close of the Transactions.

- (R) Represents the elimination of the previously recorded prepaid interest expense funded by the Company to compensate for holding the gross proceeds of the offering within an acquisition escrow account.
- (S) Represents the adjustments recorded to NSH assets and liabilities assumed based upon the preliminary valuation analysis performed.
- (T) On August 31, 2017, H.I.G. Surgery Centers, LLC. ("HIG") completed its sale of 26,455,651 shares of Surgery Partners' common stock, par value \$0.01 per share (the "Purchased Shares"), beneficially owned by H.I.G. to Bain Capital at a purchase price per share of \$19.00 for an aggregate purchase price of \$502.7 million in cash pursuant to the Common Stock Purchase Agreement. Also on August 31, 2017, Surgery Partners completed the sale and issuance of 310,000 shares of preferred stock, par value \$0.01 per share, of Surgery Partners, designated as 10.00% Series A Convertible Perpetual Participating Preferred Stock (the "Series A Preferred Stock") to BCPE Seminole Holdings LP ("Bain Capital"), an affiliate of Bain Capital Private Equity, at a purchase price of \$1,000 per share in cash (the "Preferred Private Placement") pursuant to the Securities Purchase Agreement (the "Preferred Stock Purchase Agreement"), dated as of May 9, 2017, by and among the Company and Bain Capital.

As of August 31, 2017, prior to giving effect to the Preferred Private Placement, the Purchased Shares represented approximately 54% of the outstanding Common Stock of the Surgery Partners. As a result of the Private Sale and the Preferred Private Placement, Bain Capital holds Series A Preferred Stock and Common Stock that represent approximately 66% of the voting power of all classes of capital stock of the Company as of August 31, 2017, and H.I.G. and its affiliated investment funds no longer own any capital stock of Surgery Partners. The Private Sale and the Preferred Private Placement were funded by Bain Capital through an equity financing/equity commitment letter.

Following the completion of the Private Sale, Bain Capital became the controlling stockholder of the Company. In connection with the change of control, the Company elected to apply "pushdown" accounting by applying the guidance in Accounting Standards Codification Topic ("ASC") 805, Business Combinations. In accordance with ASC 805, all identifiable assets and liabilities of the Company were measured at and adjusted to fair value as of August 31, 2017, and similarly goodwill was recognized based on the terms of the transaction and the fair value of the new basis of net assets of the Company. These adjustments represents the adjustments recorded to Surgery Partners' assets and liabilities based upon the the Company's pushdown accounting analysis performed and also includes the effects of movements in working capital from June 30, 2017 and August 31, 2017.

- (U) Represents an indemnification escrow long-term receivable and liability recorded as a result of the NSH Acquisition.
- (V) Represents the following adjustments to depreciation and amortization expense for Surgery Partners pushdown accounting.

(dollars in thousands)	l Year Ended Six nber 31, 2016	Months Ended June 30, 2017
Pro forma depreciation and amortization ⁽¹⁾	\$ 24,413 \$	12,207
Less: Depreciation and amortization, adjusted	(39,551)	(22,525)
Pro forma adjustment	\$ (15,138) \$	(10,318)

⁽¹⁾ Represents adjustments to reflect the differences in depreciation and amortization expense historically recorded and what would have been recorded during the same periods.

(W) Represents the change in interest expense as a result of the change in fair value of the Company's long-term debt based upon the preliminary valuation analysis performed.